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List of abbreviations
ANP Acyclic nucleoside phosphonate
AP1 Adapter primer 1
APOT-PCR Amplification of papillomavirus oncogene transcripts PCR
AZF  Artificial zinc fingers
BAC Bacterial artificial clone
BP Basepair
CEP Centromere
CGH Comparative genomic hybridization
CIN Cervical intraepithelial neoplasia
CPP Cell-penetrating peptide
CR/RT Combined resection plus radiotherapy
CT Chemotherapy
DAPI 4',6-diamidino-2-phenylindole
DFS Disease-free survival
DIPS-PCR Detection of integrated papillomavirus sequences PCR
DSS Disease-specific survival
EGFR Epithelial growth factor receptor
EMT Endothelial-to-mesenchymal transition
E-proteins Early proteins
FISH Fluorescence in situ hybridisation
H2O2 Hydrogen peroxide
HNSCC Head and neck squamous cell carcinoma
HPMPC [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]
HPRT Hypoxanthine guanine phosphoribosyl transferase
HPV Human papillomavirus
HR-HPV High-risk human papillomavirus
IFN Interferon
IQR Interquartile range
ISH In situ hybridisation
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OER Oxygen enhancement ratio
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ORF Open reading frame
OS Overall survival
OSCC Oral squamous cell carcinoma
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PCR Polymerase chain reaction
PI Protease inhibitors
pRb Retinoblastoma tumor suppressor protein
RNAi RNA interference (small interfering RNA)
RRP Recurrent respiratory papillomatosis
RT Radiotherapy
SER Sensitivity enhancement ratio
SPT Second primary tumor
SSC Saline-sodium citrate
TORS Transoral robotic surgery
TP63 Tumor protein p63
Tregs CD4+/CD25+ regulatory T-cells
TSCC Tonsillar squamous cell carcinoma
UCSCC Uterine cervical squamous cell carcinoma
VLP Virus-like particles
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Introduction
Viral carcinogenesis
A wild cottontail rabbit was shot in 1931 which carried three prominent subcutaneous 
tumors but otherwise appeared in good general condition. The rabbit was taken to the lab 
of Dr. Richard Shope at The Rockefeller Institute for Medical Research in Princeton, New 
Jersey, who studied hog cholera at that time. He discovered that this tumor-like condi-
tion could be transmitted to laboratory and wild cottontail rabbits by inserting small bits 
of the original tumor under the skin1. The nature of the etiological agent causing these 
tumors was identified as a virus, not related to myxomatosis2, which was known to cause 
nodules in the skin in the neighborhood of the eyes, ears, nose, mouth and genitalia3. 
Around the same time, dr. Shopes attention was drawn to a group of wild cottontail rab-
bits that carried horn-like outgrowths on the skin4 (figure 1). 
Transplants of these “warts” were transmissible to both wild and domestic rabbits 
and the properties of the papilloma-inducing agent proved to be a filterable virus. Dr. 
Shope decided to ask his Rockefeller collegue Dr. Peyton Rous to further investigate these 
rabbits, who showed that the outgrowths were in fact a benign tumor type5. When infect-
ing domestic rabbits with the virus, the papillomas often transformed into epidermoid 
carcinomas, thereby demonstrating a link between papillomavirus infection and carcino-
genesis in animals6. Dr. Rous was awarded the Nobel Prize in Physiology or Medicine in 
1966 for his discovery of tumor-inducing viruses7.
The first human virus with oncogenic properties was described more than 20 
years later. Two research groups, i.e. Trentin and collegues8, and Huebner and collegues9, 
independently showed that when human adenovirus was injected in newborn hamsters, 
Figure 1. Wild cottontail rabbit with papillomas (www.nytimes.com)
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they regularly produced visible tumors. Especially adenovirus types 12 and 18 proved to 
have oncogenic properties. However, only rodents seem to be susceptible to adenovirus-
induced carcinogenesis, and infection has not been linked to human cancer10. 
In 1965, persistent viral infection was shown in a cell line derived from Burkitt’s 
lymphoma11. DNA of this virus, later known as Epstein-Barr virus (EBV), was also shown 
in a Burkitt’s lymphoma cell line that was thought to be virus-free12. The link between 
infection with EBV and the development of Burkitt’s lymphoma and nasopharyngeal car-
cinomas was shown in 197013. 
HPV and human cancer
The cause of cervical cancer has long suspected to be a sexually transmittable virus, since 
it was observed that especially married women and prostitutes developed this disease 
and that cervical cancer was virtually non-existent in nuns. When dr. Harald zur Hau-
sen was appointed chairman of the newly established Institute of Clinical Virology in 
Erlangen-Nürnberg in 1972 he tried to identify the causative agent. The main suspect 
at this time was Herpes Simplex type 2 (HSP-2). However, attempts to amplify HSP-
2 sequences from cervical cancer biopsies failed. When he observed that genital warts 
could progress to squamous cell carcinomas in some cases14, he hypothesized that the 
papillomavirus identified in these warts might be the causative agent in cervical cancers. 
However, viral DNA extracted from plantar warts could not be detected in either genital 
warts or cervical biopsies. He further hypothesized that more types of papillomaviruses 
existed. In 1979 his group succeeded in isolating HPV6 from genital warts15, and isolation 
of HPV11 followed a little later from a laryngeal papilloma16. Research on cervical cancer 
biopsies showed that these sequences could be identified in these malignant lesions as 
well16. In 198317 and 198418 HPV16 and -18 were successfully cloned and were shown to 
be present in about 50% and 20% of cervical cancer biopsies, respectively. Later research 
showed the presence of HPV in precursor lesions, indicating a prominent role for HPV 
in cervical carcinogenesis. 
Since the discovery of HPV the link between HPV infection and carcinogenesis 
became convincingly established and HPV was identified in more carcinomas. HPV in-
fection was first linked to laryngeal cancers19, to esophageal cancer20 and oral cancer21, 
before being associated with oropharyngeal cancers22. Later studies revealed that particu-
larly HPV16 is involved in head and neck cancers and that the presence of the virus is 
especially common in the oropharynx23-25 (see chapter 2). 
To date, many advances have been made in the characterization and identification 
of HPVs, and currently around 200 types of HPV are known, of which 15 are character-
ized as high risk, or oncogenic types. The identification of a consistent expression of the 
13 
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viral genes E6 and E7 eventually lead to the development of an HPV vaccine. In 2008, 
professor Harald zur Hausen was awarded the Nobel-prize in Physiology or Medicine for 
his discovery of human papilloma viruses causing cervical cancer 26. 
Transmission of HPV
HPV is the most common sexually transmitted virus. Having multiple sex partners has 
been linked to an increased risk of developing cervical and oral cancer (see chapter 2). 
It has even been shown that husbands of wives with cervical carcinoma have a  higher 
risk for developing head and neck squamous cell carcinomas (HNSCC). HPV can also be 
acquired via non-sexual contact such as deep kissing27 and may even be transmitted via 
hands28. In addition, it can be transmitted from mother to child during delivery. This has 
been shown to result in a 33% higher chance of oral HPV infection in newborn infants 
born to an HPV-positive mother as compared to children born to HPV-negative moth-
ers29. In addition, several reports have shown the presence of HPV in umbilical cord blood 
and placenta30. Another possible route of transmission is via blood, since the presence of 
HPV was detected in blood of healthy male blood donors31. HPV particles are suspected 
to adhere to peripheral blood mononuclear cells, which might represent a so far unknown 
reservoir for HPV particles31. 
HPV infection
HPVs are non-enveloped double-stranded DNA viruses that infect the basal cells of cu-
taneous and mucosal epithelia (see chapter 2). Infection with HPV can occur when mi-
crolesions expose the basal epithelial (stem) cell layer. The basal compartment contains 
the dividing cells in the epithelium, and generates other basal cells by sideways division 
and keratinocytes by upward division32. Following cell division, one daughter cell de-
taches from the basement membrane, migrates towards the suprabasal layers and begins 
terminal differentiation. During this process the cell exits the cell cycle. The papilloma-
virus life cycle is tightly linked to the differentiation program of the infected epithelium. 
After infection, viral DNA is maintained in the basal cells as nuclear episomes at ap-
proximately 50-100 copies/cell. Viral DNA is partitioned equally during cell division33. 
This requires the expression of the viral E1 and E2 genes. When the keratinocyte reaches 
the suprabasal layer and starts terminal differentiation, expression of the viral oncogenes 
E6 and E7 drives the cells into S-phase, causing increased proliferation of the suprabasal 
cells and replication of the viral genome above the basal cell layer. Eventually, productive 
infection is initiated when the two capsid proteins L1 and L2 are synthesized and the 
14
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replicated viral genome is packaged into infectious particles. HPV is a non-lytic virus and 
infectious particles are present in cells that are shed from the epithelial surface at the end 
of their life span33 (see figure 2). 
Under normal circumstances, HPV remains in an episomal state and infection 
with the virus is transient. However, due to reasons that are so far not understood, the 
viral DNA can break and integrate into the host genome. This is believed to be an im-
portant step in cellular transformation of HPV-infected mucosa. Integration is thought 
to induce a deregulation of the cell cycle control and therefore uncontrolled cellular 
proliferation, dependent on constitutive expression of the viral oncogenes E6 and E734. 
However, although the relation between integration and increased viral oncogene ex-
pression has been clearly shown in cell line models, it is still unclear whether it exists in 
primary carcinomas35-39. 
Much of the current information on HPV-associated carcinogenesis is based on 
information provided by studies in cervical dysplasias and cervical carcinomas, as well 
as cell lines derived thereof. HPV infection is an imperative, albeit not sufficient, cause 
for the development of cervical carcinomas. Despite several etiological similarities, our 
knowledge on the role of HPV in cervical (pre)malignancies cannot be translated one-to-
one to the head and neck region. 
Although there is an evident association of HPV with HNSCC in a subgroup of 
patients, infection with HPV is not an essential factor in most HNSCC. The classical risk 
factors, such as tobacco and alcohol consumption, are still responsible for a large fraction 
of these cancers. Morphological and physiological characteristics of different anatomical 
Figure 2. Life cycle of HPV with the timing of viral gene expression during epithelial differentiation (adapted from Door-
bar et al., 2006)33.
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sites affected by HPV-related carcinomas differ considerably, and therefore it is perilous 
to extrapolate thoughtlessly information on HPV infection and the effects on tumor biol-
ogy from cervical carcinomas to HNSCC. 
This thesis will focus on oropharyngeal cancer since a large proportion of HPV-
induced HNSCC originate from this anatomical location23-25. For clarity, the term oro-
pharynx refers to the anatomic region that includes the soft palate and uvula, tonsils, 
posterior pharyngeal wall and the base of tongue (see figure 3). 
Figure 3. Cross-cut of the human head and neck region. The oropharynx is indicated by the black rectangle. Copyright 
© 2013, ec-europe. Http://apps.ec-europe.com
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Aim of the thesis
The aim of this thesis is to enhance our understanding of clinical and biological fea-
tures of HPV-associated oropharyngeal carcinomas. For this purpose, HPV-associated 
HNSCC tumor samples, as well as established cell lines derived from such tumors, were 
analyzed. The presence and/or physical status of the virus was correlated to their clinical 
and biological behavior.
The following questions were addressed:
1.  Do HPV-associated HNSCC exhibit different molecular and clinical features as 
compared to HPV-negative HNSCC and if so, do these features offer possible 
therapeutic targets? 
Chapter 1 contains a review on the clinical and molecular characteristics of HPV-positive 
and -negative HNSCC and possible ways to target specifically the HPV-infected cells to 
improve therapy for this group of patients. This clearly indicated that HPV-associated 
HNSCC form an etiologically distinct group of carcinomas in the head and neck region. 
Patients with HPV-associated carcinomas generally have a better prognosis and response 
to treatment. In HNSCC in general, N-status is considered to be the most reliable prog-
nostic marker40-42. The literature is, however, not consistent in confirming its prognostic 
value in tonsillar carcinomas43-45. Therefore, the question was raised:
2.  What is the prognostic value of N-status in relation to HPV positivity in tonsillar 
squamous cell carcinomas?
Chapter 2 involves a clinical study in which the prognostic value of N-status in a cohort of 
81 patients with tonsillar cancer was examined. Nodal involvement was shown to correlate 
to an unfavourable prognosis in HPV-negative patients, but this effect was not seen in 
HPV-positive patients. HPV integration into the host genome is closely linked to progres-
sion in cervical cancers, and integration is found in approximately 55% of HPV16 positive 
uterine cervical carcinomas46. However, high variation in integration frequencies has been 
reported in HNSCC24,47, which led to the following question:
3.  What is the frequency and genomic site of HPV-integration in HPV-associated 
HNSCC?
Chapter 3 describes the analysis of tumor biopsies from a cohort of 75 patients with HPV-
associated HNSCC to assess integration frequency and identify integration loci. Integra-
tion could be detected in 39% of the tumours, with integration loci distributed througout 
17 
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the entire genome. Although studies in cell lines have shown that HPV integration results 
in higher expression of the viral oncogenes E6 and E738, this information is lacking for 
primary HNSCC, giving rise to the question:
4.  Is there a correlation between the viral integration status and the expression of the 
viral genes?
In chapter 4 the viral physical status was correlated to the expression of the viral E2, E6 
and E7 genes and to a number of virally-disrupted human genes. This showed a large 
variation in viral gene expression, independent of the physical status of HPV. Finally, 
well-established cell line models are important tools in the development of antiviral 
therapies that might improve prognosis of patients suffering from these carcinomas. The 
question therefore emerged:
5.  Can cell lines derived from HPV-associated HNSCC tumors be employed in the 
research for therapeutic options beneficial for HPV-positive HNSCC?
Chapter 5 involves the characterization of 7 HPV-associated HNSCC cell lines to further 
study integration and to establish a reliable cell line model for HPV-associated HNSCC 
cancers. This indicated that these cell line models exhibit characteristics that are associ-
ated with a poor prognosis in primary HPV-positive HNSCC, such as EGFR overexpres-
sion and aneusomy48,49. This indicates that these cell lines represent proper model systems 
for in vitro testing of treatment modalities. Previous studies have shown enhanced radio-
sensitivity for HPV-positive HNSCC50. Since the efficiency of radiotherapy is dependent 
on the tissue oxygenation, this might indicate that HPV-positive tumors are less hypoxic. 
In contrast, PET/CT showed that HPV-positive and -negative tumors were equally hy-
poxic51. The purpose of the study described in chapter 6 was to:
6. Examine the biological background for these clinical observations.
The study described in chapter 6, using a panel of HPV-positive and -negative HNSCC 
cell lines, shows that, although HPV-positive cells had a markedly higher radiosensitivity 
compared to HPV-negative cells, they displayed the same relative radioresistance under 
hypoxia and the same relative sensitizer effect of Nimorazole. No difference was found 
in the expression levels of hypoxia-inducible genes between HPV-positive and -negative 
cell lines. 
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Abstract
Oncogenic human papillomavirus (HPV) is currently recognised as a  major risk fac-
tor for the development of head and neck squamous cell carcinomas (HNSCC). HPV is 
mostly detected in tumours arising from the oropharynx and more specifically from the 
tonsil. HPV-related tumours display clinical and molecular characteristics that are dis-
tinct from HPV-unrelated tumours, which are generally induced by alcohol and tobacco 
abuse. Detection of biologically active HPV in HNSCC has prognostic relevance, which 
warrants the separate classification of HPV-induced tumours, and is a prerequisite for 
further optimisation of treatment protocols for this distinct group. Current guidelines 
for the treatment of oropharyngeal squamous cell carcinoma (OPSCC) have not incor-
porated specific treatment modalities for HPV-related tumours. The development of such 
treatment options is still in a preclinical phase or in early clinical trials. Recent data on 
treatment response of OPSCC have been obtained by retrospectively analysing HPV-
status and indicate that patients with HPV-related tumours show a favourable progno-
sis, independent of the type of treatment. These patients may benefit from de-intensified 
treatment, which should be assessed in prospective clinical trials. The development and 
future use of new antiviral and immunomodulatory therapeutics may be instrumental in 
this approach to improve survival rates and decrease disease- and treatment-related mor-
bidity. In this review we will focus on present therapeutic HPV-targeting strategies and 
discuss future directions for de-intensified treatment of HPV-positive HNSCC. 
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Introduction
Head and neck cancer is a serious health care problem in many parts of the world1. The 
vast majority of head and neck cancers are squamous cell carcinomas originating from 
the mucosal epithelium lining the oral cavity, nasal cavity, pharynx and larynx2. In 2008, 
head and neck squamous cell carcinomas (HNSCC) were estimated to cause 480.000 new 
cancer cases and 273.000 cancer deaths worldwide1. Despite the fact that advances have 
been made in diagnosis and treatment, mortality rates have only marginally decreased 
over the last decades and the 5-year survival rate currently ranges between 40%–60%3. 
Approximately 80%–90% of HNSCC develop in patients with a history of alcohol and 
tobacco abuse, including tobacco and betel quid chewing and snuff dipping4. These fac-
tors are also responsible for the process of “field cancerization” in the entire head and 
neck region5, leading to multiple primary tumours in up to 40% of patients6. Patients 
without exposure to these risk factors account for 10–20 % of HNSCC. These tumours 
are predominantly associated with viral carcinogenesis, including infection with EBV in 
nasopharyngeal carcinomas7 and, to a greater extent, infection with oncogenic human 
papillomavirus (HPV) in the oropharynx, in particular in the lingual and palatine tonsils. 
In the last decade the incidence of HPV-related oropharyngeal squamous cell carcinoma 
(OPSCC) has increased relative to the total group of HNSCC4,8. Infection rates in OPSCC 
range from 20 to more than 90% in different studies, depending on geographical factors 
and the detection method used9-12. 
In this review we will present the clinical and molecular features of HPV-positive 
HNSCC. Subsequently we will focus on the current knowledge of potential anti-HPV strate-
gies and discuss the most promising modalities for the treatment of HPV-positive HNSCC. 
Methods
Besides relevant articles selected from the general literature concerning HPV-related car-
cinogenesis and references therein, specific literature on treatment options for HPV-re-
lated HNSCC was obtained by a bibliographical search in Pubmed, Medline and Embase, 
from inception to May 2011, using the search term (HPV OR papillomavirus OR papil-
loma) AND (HNSCC OR “head and neck cancer” OR oropharyngeal OR oropharynx OR 
oral OR pharyngeal OR pharynx OR buccal OR base of tongue OR tongue OR tonsillar 
OR tonsil OR floor of mouth OR mouth OR vallecula) AND (treatment OR antiviral OR 
therapy) AND (cancer OR carcinoma OR tumor OR tumor OR neoplasm). This search 
yielded 1246 results in PubMed, 137 in Medline and 309 in Embase. Based on inspection 
of the title and/or abstract of these publications, 63 relevant papers on treatment options 
and some references therein were included in this review. Moreover, ongoing clinical 
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trials concerning new therapeutic options for HPV-related HNSCC were identified from 
the Cochrane Controlled Trial Register and from the US National Institute of Health 
Clinical Trials (www.clinicaltrials.gov), yielding 5 relevant results. 
HPV and tumourigenesis
Human papillomavirus
HPVs are non-enveloped viruses, containing circular double-stranded DNA of approxi-
mately 8 kb, that are highly epitheliotropic and known to infect both mucosal and cuta-
neous epithelia13. Papillomaviruses are species-specific and the human papillomavirus 
family can be classified into 5 genera and subdivided into 31 species and 120 types14. 
A subgroup of 15 HPV types is linked to the development of malignant lesions of mucosal 
and cutaneous epithelia, and is considered to comprise high-risk (HR) HPVs15. All HR-
HPVs belong to the alpha-genus, including HPV-16 and -18 which are found in ~50% 
and ~20% of cervical malignancies, respectively16. Differences in the capacity to deregu-
late cellular protein function by viral oncogenes E6 and E7 account for the carcinogenic 
properties of HR-HPV in comparison with low risk (LR) HPVs17,18. LR-HPV types, such 
as HPV-6 and -11, are often found in benign mucosal lesions and are only sporadically 
associated with carcinomas. Human lesions in which HPV types of the alpha-genus ap-
pear to be involved are summarised in table 1. 
Human papillomavirus replication and integration
The HPV life cycle is linked to the differentiation of the infected epithelial cell. HPV in-
fection is initiated by binding of the virion L1 protein to heparan sulphate proteoglycans 
(HSPG) on segments of the basement membrane, which are exposed at sites of (micro)
injury. This induces conformational changes and L2 cleavage finally resulting in binding 
of the L1 capsid protein to a so far undetermined cell surface receptor19. The cell adhesion 
receptor α6-integrin has been implicated to be this receptor20, but does not seem to be 
essential for HPV infection. However, α6-integrin might be a matrix component closely 
associated with HSPG21. The circular HPV DNA codes for 6 early (E) and 2 late (L) pro-
teins (figure 1). The E-proteins regulate and facilitate virus-replication and are expressed 
early after infection22. Oncoproteins E6 and E7 have a direct effect on several essential 
cellular processes, such as cell cycle and apoptosis regulation. E6 promotes degradation 
of p53 through interaction with E6-associated protein (E6AP), an E3 ubiquitin ligase, 
and subsequent ubiquitination and proteasomal degradation. Amongst others, this alters 
transcription of p53 target genes and activates human telomerase reverse transcriptase 
(hTERT), resulting in cell survival and ultimately in genetic instability23,24. The oncopro-
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tein E7 binds to the unphosphorylated retinoblastoma tumor suppressor protein (pRb), 
which promotes the release of transcription factor E2F, leading to activation of the cell 
cycle and transition through the G1/S-phase, needed for DNA-replication25-27. 
As a consequence, p16INK4A is upregulated but is unable to properly inhibit the cell 
cycle. Expression of oncoproteins E6 and E7 is tightly regulated by E2, the main regulator 
of viral gene transcription28. Molecular studies have shown that integration of HPV often 
leads to a disruption in the E1/E2 open reading frame, and concurrent loss of the E4 and E5 
and parts of the E2 and L2 genes29. E2 function can moreover be abrogated by epigenetic al-
terations of the viral genome such as methylation of the E2 binding site in the long control 
region30. Absence of E2 function results in upregulation of the expression of oncoproteins 
E6 and E7, which in turn leads to uncontrolled cell cycle progression (see figure 1). 
The major structural protein L1 of the HPV capsid is sufficient for self-assembly 
into a capsid, but entry of the virus into the cell is co-dependent on L2, the minor struc-
tural protein19,31. 
Under normal circumstances HPV maintains an episomal state, and infection 
with HPV is transient. In a recent prospective cohort study, the reported average duration 
of active episomal infection in the uterine cervix appears to be approximately 8 months32. 
Although uterine cervical HPV infection prevalence decreases with increasing age33, it is 
unclear whether age affects the duration of infection. Persistent infection, however, might 
lead to integration of the virus34,35. 
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Table 1. Involvement of HPV-types of the alpha-genus in benign and malignant human lesions. The major 
HPV types for the different lesions are indicated in bold. 
Lesion HPV types found References
Head and neck benign
Focal Epithelial Hyperplasia 13, 32 [176, 177]
Sinonasal papilloma 6, 11, 18 [178, 179]
Laryngeal papilloma and dysplasia 61), 11, 16, 18 [180, 181]
Oral leukoplakia and lichen planus 6, 16, 18, 31, 33 [182, 183]
Head and neck malignant
Oropharyngeal squamous cell carcinoma 6, 11, 16, 18, 31, 33, 35 [52], this review
Oral squamous cell carcinoma 16, 18 [52, 60]
Laryngeal squamous cell carcinoma 6, 11, 16, 30 [52, 60]
Sinonasal carcinoma 16, 18 [179]
Anogenital
Anogenital2) benign lesions3) 6, 11, 16, 18, 31, 33, 56, 56, 58, 66, 70 [36, 184]
Anogenital2) (squamous cell) carcinoma 6, 11, 16, 18, 31, 33, 45 [36, 184]
Cervical intraepithelial neoplasia and 
uterine cervical squamous cell carcinoma
6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68, 70, 73, 82
[16, 37]
Adenocarcinoma in situ and uterine 
cervical adenocarcinoma 16, 18, 33, 35, 45, 51, 58, 59 [185, 186]
Cutaneous
Common skin warts 2, 3, 7, 10, 27, 28 [15, 187]
Periungual squamous cell carcinoma 16, 26, 33, 51, 56, 73 [188, 189]
1) The major HPV types for the different lesions are indicated in bold; 2) including anal, vulvar, vaginal and 
penile lesions; 3) including warts, lichen sclerosis, squamous cell carcinoma in situ, adenocarcinoma in situ 
and intraepithelial neoplasia. 
Numerous investigations have shown an etiological relationship between infec-
tion with HR-HPV infection and the development of uterine cervical squamous cell car-
cinomas (UCSCC) and other anogenital squamous cell carcinomas36,37. More than 90% of 
UCSCC contain and express HR-HPV sequences, which are predominantly present in an 
integrated form38,39. HPV-16 is the most common HPV type and is detected in more than 
50% of UCSCC, followed by HPV-18, -33 and -4537,40 (table 1). 
The precise relationship between HR-HPV integration and head and neck car-
cinogenesis is less clear, partly because primary premalignant lesions of the oropharynx 
are seldom detected. Although controversial data have been reported41-44, integration of 
HR-HPV in OPSCC is a prevailing finding. 
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HR-HPV in HNSCC
Patients with a history of HPV-related anogenital carcinomas, patients seropositive for 
HPV-16, and husbands of patients diagnosed with uterine cervical dysplasia or carci-
noma in situ all show increased risk rates for developing OPSCC45-47. 
The involvement of HPV in head and neck tumourigenesis was first proposed 
by Syrjänen et al.48, who showed histopathological features of HPV infections in 40% 
of patients, and HPV-positive nuclei in 20% of patients using immunohistochemistry. 
Since then many studihave provided evidence that infection with HR-HPV is a signifi-
cant independent risk factor for HNSCC and is associated with high risk sexual behav-
iour9,10,49-51. HR-HPV positive tumours are most frequently found in the oropharynx, and 
are associated with HPV-16 in >90% of cases9,49,52,53. Because patients with OPSCC often 
present with metastatic disease at first diagnosis, information on the persistence of oro-
pharyngeal HPV infections and premalignant lesions in this region is scarce54-56. HPV 
prevalences of less than 1% have been found in tumor-negative tonsillar tissue samples, 
screened for HPV with PCR51,57,58. 
HR-HPV detection and tumor characteristics
The reported overall incidence of HPV in OPSCC ranges from less than 20% to more 
than 90% in different studies. This variation depends on several factors, including geo-
graphical features, sample preparation and detection methods used, but also the amount 
and manner of tobacco consumption depending on geographical location9,12,54,59-61. It has 
been shown that not all tumours tested positive for HPV DNA can be regarded as etiolog-
ically HPV-related50,62. A clinically relevant infection, i.e. a transcriptionally active infec-
tion should be present, which can be demonstrated by detectable expression of the viral 
oncogenes E6 and E763. This correlates strongly with overexpression of the CDK inhibitor 
p16INK4A, which is considered a reliable surrogate marker for HR-HPV infection in most 
cases41,64. A reliable algorithm for HPV detection should thus start with p16INK4A detec-
tion, followed by in situ hybridisation (ISH) and/or RT-PCR analysis of E6/E7 transcripts 
after HPV typing41, as suggested by two recent reports59,65. A representative example of 
these analyses is shown in figure 2. 
HPV-associated OPSCC are now considered to comprise a separate entity with 
typical clinical and molecular features. Table 2 summarises the major differences between 
HPV-positive and -negative OPSCC. 
HPV-positive OPSCC are characterised by overexpression of oncoproteins E6 and 
E7 leading to degradation of p53 and pRb, thereby inducing cell cycle and apoptosis de-
regulation. As a result, CDK inhibitors including p16INK4A, p14ARF, p18INK4C and p21Cip1/WAF1 
are upregulated, which subsequently leads to downregulation of cyclin D1 and inhibition 
of complex formation with CDK422,62,66,67. In HPV-negative tumours cell cycle deregula-
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Figure 1. Structure of circular episomal and linear integrated HPV DNA. The HPV genome is usually present in many epi-
somal copies in the nucleus of infected cells. In the transition to cancer, viral DNA often integrates in 1 or more copies into 
the host genomic DNA. During this process, the ring structure of the HPV-DNA molecule is most often opened within the 
E2 reading frame, frequently leading to deletion of E4 and E5 and part of E2 and L2. The subsequent upregulation of E6 
and E7 oncoproteins results in deregulation of cell signalling pathways which, amongst others, leads to increased cellular 
proliferation and inhibition of apoptosis. Based on [172-175].
Figure 2. Representative examples of strong nuclear and cytoplasmic p16INK4A immunostaining (A) and punctate nuclear 
HPV-16 FISH signals indicating viral integration (B) shown on paraffin embedded, formalin fixed tissue sections of OP-
SCC. An example of E6-specific HPV-16 RT-PCR products on a 1% agarose gel, on RNA extracted from cell lines and 
fresh-frozen OPSCC tumor tissues, are shown in (C). 
31 
Chapter 1
tion is established by p53 and pRb gene mutations, or alternatively by inactivation of 
p16INK4A and p14ARF gene expression through mutation, promoter hypermethylation or 
homozygous deletion22, or activation of cyclin D1 expression via 11q13 amplification68. 
High expression of EGFR by transcriptional upregulation is generally present in this OP-
SCC subgroup22,56,62,66-68. Upregulation of EGFR expression is usually not seen in HPV-
positive OPSCC56,67,69-71.
In addition, global genome and protein scanning approaches have been and are 
being used to unravel DNA, mRNA, microRNA and protein signatures specific for HPV-
positive and - negative OPSCC. So far these studies revealed that HPV-positive tumours 
exhibit a relatively stable genome with 11q and 16q loss72-74, and upregulate transcription-
al activity of cell cycle regulators (as mentioned above), transcription factors (e.g. TFDP2, 
ZNF238, TAF7L and RPA2) and DNA repair proteins (e.g. RFC4 and RFC5). Also, HPV-
positive tumours show decreased expression of genes involved in immune responses (e.g. 
IFIT1, IFITM1-3, IFI6-16, IFI44L, OAS2, and IFN-κ)68,75-79. In addition, these tumours 
differentially express microRNAs, and for example upregulate miR-363 (belonging to 
the oncogenic miR-106a-363 cluster), and downregulate miR-218 . A recent proteome 
analysis comparing HPV-positive and -negative oral squamous cell carcinomas (OSCC) 
reported upregulation of thioredoxin and epidermal-fatty acid binding protein80. Thiore-
doxin is an important redox-mediator that stimulates cell growth and inhibits apoptosis 
under adverse conditions, apparently including HPV infections, as also seen in cervical 
carcinomas. Epidermal fatty-acid binding protein, although mainly involved in fatty acid 
uptake, transport and metabolism, also functions in cellular signalling, affecting differ-
entiation, growth regulation and gene expression80. Although expression of 3q-specific 
genes has been reported as being specific for HPV-positive OPSCC , this finding remains 
to be confirmed, since extra copies of 3q-genes have been found in both HPV-positive 
and -negative tumours68,77. 
Current treatment of OPSCC and effect of HR-HPV 
status on treatment response
Current treatment modalities
Current international clinical guidelines for HNSCC treatment mention HPV as a risk 
factor for OPSCC. The American National Comprehensive Cancer Network has sug-
gested to include HPV detection in the diagnostic work-up of these tumours81. However, 
the treatment guidelines do not offer therapeutic modalities specific for HPV-related tu-
mours. Current therapeutic options include surgery, radiotherapy chemotherapy (CT), 
immunomodulatory therapies or combinations of the foregoing. Surgery as primary 
treatment avoids toxicity caused by radiotherapy and CT, but causes loss of function, par-
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ticularly in patients with larger tumours. The development of laser surgery and transoral 
robotic surgery (TORS) for OPSCC reduces functional morbidity as a consequence of 
three-dimensional visualization and the ability to manipulate and perform reconstruc-
tion of the oropharynx without the need for an open surgical approach82,83. Regional in-
filtration of critical structures, and thus unacceptable loss of function after surgery can 
classify a tumor as functionally or technically unresectable. In those cases radiotherapy 
and/or CT is the treatment of choice84 when aiming at restoring function, however with 
the disadvantage of therapy-related local and systemic side effects85. The final choice of 
treatment is based upon clinical variables such as tumor type, localisation and stage86, age 
of the patient, general medical and psychomedical condition81 and individual preferences 
of the patient.
Effect of HR-HPV status on outcome
In retrospective studies, HR-HPV- and/or p16INK4a positive tumours have been found to 
respond better to multimodal therapies as compared to HPV-negative tumours, there-
by favouring patient survival41,42,53,64,87,88. More recent retrospective studies have shown 
that this favourable outcome is independent of treatment modalities89-95. However, the 
heterogeneity of the HNSCC patient populations, and consequent variability with re-
gard to the HPV and/or p16INK4A status, as well as applied treatment protocols has most 
probably negatively influenced the association between HR-HPV status and outcome in 
these studies . It can be anticipated that the actual difference in clinical outcome between 
HPV-positive and -negative cases will become even more pronounced when compar-
ing a homogeneous population of OPSCC and application of reliable detection methods 
for clinically relevant HPV-infections. Prospective clinical trials are required to further 
validate HR-HPV presence as predictive factor for therapy outcome and to determine 
whether treatment de-intensification might improve quality of life while preserving the 
favourable clinical outcome in HPV-positive OPSCC patients96,97. 
An explanation for the favourable response may lie in the fact that, although the 
pRb- and p53-pathways are compromised in HPV-positive tumours, they retain some 
function, such that under the pressure of radiotherapy and/or CT, p53-mediated apop-
totic pathways may still function. The presence of wild-type p53 in combination with low 
levels of Bcl-2/Bcl-xL and EGFR, which are features of HPV-positive tumours in non-
smokers, may enhance this treatment advantage9,53,63,67,69,71. Moreover, limited tobacco 
and/or alcohol use reduces field cancerisation and the chance of developing a second pri-
mary tumor or distant metastasis in HPV-positive tumours41,53,93, which underscores the 
need to investigate the effect of tobacco and alcohol exposure on the biological behaviour 
of HPV-positive OPSCC, as recently proposed41,94. 
Besides the overall better survival of patients with HPV-positive tumours, their treat-
ment may be further improved by the implementation of strategies that either 1) promote 
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the immune response to eradicate the virus, 2) inhibit viral DNA replication, 3) specifically 
target viral oncoproteins or 4) have an effect on deregulated signal transduction pathways 
specific for HPV-positive tumor cells. In the following section we review these strategies, 
their mode of action and possible benefits for patients with HPV-induced HNSCC.
Prophylactic and therapeutic alternatives  
for HPV-positive OPSCC
Immunomodulating therapies
Vaccination 
Two prophylactic vaccines, containing recombinant virus-like particles (VLP) com-
posed of the L1 proteins of the respective HPV types31, have been marketed recently, 
i.e. Cervarix® (GlaxoSmithKline) and Gardasil® (Merck). Both vaccines have been 
FDA-approved for use in girls and young women98,99 and Gardasil® has also been ap-
proved for use in men100. 
Cervarix® is a bivalent vaccine that protects against infection with HPV-16 and 
-18 whereas the quadrivalent vaccine Gardasil® provides protection against HPV-6, -11, 
-16 and -18. 
Reports indicate that Cervarix® also offers cross-protection against HPV-31, -45 
and -52101,102, and Gardasil® possibly against HPV-31103. More robust cross-protection may 
be induced by adding L2 minor capsid proteins to the vaccine104. Both vaccines induce 
high antibody titers, seem to be well-tolerated and safe and provide >90% protection in 
HPV-16 and -18 naïve females when given in three doses within six months102,105. Cur-
rently only young HPV-naïve females are vaccinated, since vaccination of women ac-
tively expressing HPV-16 or -18 at study entry did not result in decreased development of 
cervical intraepithelial neoplasia (CIN) lesions102,105 However, vaccination with Gardasil® 
also provided >90% protection in women with evidence of past infection (seropositive 
and HPV DNA negative) with one or more of the HPV-types against which the vaccine is 
directed106,107. Long-term benefits of vaccination are not yet known, but it is hypothesised 
that vaccination could also strongly reduce the number of HPV-related OPSCC. This 
would indicate that HPV-naïve boys and young men should be vaccinated as well, since 
HPV-related OPSCC is diagnosed in males more often than in females61,69. However, see-
ing that patients usually present with HPV-related head and neck tumours from the fifth 
decennium of life onwards, the efficiency of vaccination in these patients will only be-
come evident within a few decades. 
Patients with HPV-related disease may benefit from the development of thera-
peutic vaccines. These vaccines are designed to induce cell-mediated immunity against 
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the overexpressed foreign viral oncoproteins, particularly E6 and E7. There are four 
classes of therapeutic vaccines: 1) live-vector based, 2) peptide/protein based, 3) nucleic 
acid based and 4) whole cell vaccines (for a comprehensive review see108). In anogenital 
and uterine cervical lesions therapeutic vaccination has shown to generate specific im-
munological and clinical responses, including complete regression of the lesion in 22% 
of patients with CIN III lesions as reported in a study using a fusion-protein based vac-
cine109-111. A  preclinical study using a  DNA-based vaccine demonstrated that such an 
approach for therapeutic vaccination efficacious in a mouse model of HPV-related HN-
SCC112. Clinical trials to evaluate the effectiveness of therapeutic vaccination in HPV-
related HNSCC are ongoing113,114. 
Interferon
Interferons (IFNs) are cytokines that are produced by many cell types in response to in-
fection with bacteria, viruses and parasites115. Two classes of IFNs can be distinguished: 
class I consists of IFN-α and -β and class II of IFNγ. Class I IFNs are secreted from in-
fected cells and bind to the ubiquitously expressed heterodimeric interferon receptor. 
Binding of IFNα/β to the interferon receptor induces the transcription of several host 
cell proteins that inhibit viral replication in the infected epithelial cell, and leads to ac-
tivation and the production of IFNγ in dendritic cells. IFNγ can also be produced by 
activated Th1 cells. Both classes of IFNs possess antiviral and antiproliferative properties. 
IFNγ can also activate macrophages and natural killer lymphocytes, and induce translo-
cation of the major histocompatibility complex class I and II to the cell membrane115. The 
interferon response, however, is suppressed upon HPV infection, because several HPV 
proteins (E1, E6 and E7) interfere with the IFN signal transduction cascade by binding 
to e.g. Tyk2 kinase, IRF-1 and -3, p48 and p56, leading to downregulation of the levels of 
IFN-inducible genes such as TNSFS10, IFIT1 and IFI5478,116,117.
Despite this, a successful immune response to HPV is generally seen in healthy 
individuals, as for example reported in the studies of van der Burg and co-workers118,119, 
showing high frequencies of circulating CD4+ T-helper cells reacting with HPV16 E2 
and E6, indicating a cell-mediated Th1 immune response. In persisting lesions, applica-
tion of IFN therapy may restore antiviral defence mechanisms, thereby supporting ef-
fective treatment of HPV-infected lesions. IFN therapy proved to be beneficial in HPV 
infections like condylomata acuminata119,120, while the use of IFN therapy in HPV-asso-
ciated anogenital intraepithelial neoplasia has been assessed in several studies with con-
tradicting results. Improved outcome for IFN-treated patients was shown in some stud-
ies121,122, while others reported no change in response rates between treated patients and 
controls123,124. This might be attributed to the fact that local application seems to achieve 
better responses than systemic application120. In addition, it seems that IFN therapy can 
eradicate episomal HPV infection, but leads to growth advantage for cells containing 
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integrated HPV125,126. IFN-induced upregulation of p56, which blocks HPV replication 
by binding to the E1 protein and inhibits its helicase activity, may explain this effect on 
episomal infection127,128. Loss of (parts of) E1 and E2 by viral integration, resulting in 
upregulation of E6 and E7 as stated above, could explain the lack of effect of IFN treat-
ment in these cells and their selective growth advantage. On the contrary, IFN was also 
shown to increase viral early gene transcription in a cell model129. In recurrent respiratory 
papillomatosis (RRP) a long-term response to IFN-α therapy was seen in patients with 
HPV-6 related papillomas, but patients with HPV-11 related papillomas were much less 
responsive to IFN therapy130. In conclusion, the beneficial effects of IFN therapy seem to 
be limited to episomal infections, which limits the applicability of this therapy in HPV-
positive carcinomas. 
Antiviral therapy
Cidofovir
Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] (HPMPC) is a nu-
cleoside analogue of deoxycitidine monophosphate with a remarkably broad spectrum 
of antiviral activities directed against DNA viruses, including HPV and polyoma131. After 
intracellular double phosphorylation the structure resembles dCTP and can act as a com-
petitive substrate. After removal of the diphosphate group cidofovir can be incorporated 
into viral DNA during replication, resulting in selective antiviral activity for those viruses 
encoding their own DNA polymerase. Viral DNA polymerases, of for instance cytomega-
lovirus, display greater affinity for cidofovir than human cellular DNA polymerases. Al-
though HPVs do not produce viral DNA polymerases, cells infected with HPV show 
enhanced susceptibility to cidofovir-induced apoptosis as compared to non-infected cells 
for a yet unknown reason132,133. 
In 1998 it was shown by Andrei et al. that acyclic nucleoside phosphonate (ANP) 
analogues such as cidofovir show a selective antiproliferative effect in HPV-bearing tu-
mor cell lines CK-1, SiHa, CaSki and HeLa134 .This effect is partly induced by its non-
selective toxicity to rapidly dividing cells134,135. Apoptosis might also be induced by accu-
mulation of the tumor suppressor proteins p53 and p21Cip1/WAF1 132,133, although an increase 
in p53 expression was not found in the HNSCC cell line UPCI:SCC090136. However, by 
combining cidofovir with radiotherapy, the radiosensitivity of UPCI:SCC090 and other 
HPV-containing cell lines could be enhanced in vitro132,136, as well as in vivo in nude 
mouse xenografts132. CT combined with cidofovir also yielded a synergystic effect in an 
HNSCC cell line model137. One study expressed concern about using cidofovir for the 
treatment of RRP138, as it demonstrated high malignancy transformation rates in rats and 
cell lines. In humans this effect has not been reported, and cidofovir is already applied as 
an effective adjuvant therapy for HPV-induced RRP in humans139. 
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For the treatment of various HPV-related lesions the route of administration may 
be an important factor. Cidofovir can be applied systemically or topically or injected in-
tralesionally. Although concern was raised about possible nephrotoxicity in systemic use, 
this side-effect can be greatly diminished by administration of probenecid and prehydra-
tion with saline solution140. 
In a clinical setting it was shown that local therapy with cidofovir gel resulted in 
complete or partial regression of uterine CIN II and III lesions141,142 as well as vulvar and 
other intraepithelial neoplasms143,144. On the other hand, intralesional treatment with ci-
dofovir of one patient with an invasive carcinoma in the respiratory tract and a history of 
RRP only lead to minor clinical effects, limited to the superficial portion of the tumour145. 
Clinical trials using cidofovir as an adjuvant therapy in cervical cancer have start-
ed146, but trials for its application in HNSCC have to be initiated.
Interfering RNAs
RNA interference (RNAi) can be used to inactivate gene expression and so far encour-
aging results have been reported for the treatment of HPV-related carcinomas in vitro 
as well as in vivo. Chen and co-workers, for example, reported a 50% reduction of E7 
mRNA expression in HPV-6b/11 E7-expressing mouse tumor models147. RNAi against 
HPV-16 E6 and/or E7 has been shown to degrade these mRNAs leading to decreased 
expression of the gene products in both cervical as well as HNSCC cell line models. 
This resulted in restoration of pRb function and upregulation of p53 and p21Cip1/WAF1, 
leading to substantial apoptotic cell death148-150. RNAi against HPV-18 E6 and E7 has 
also seem to possess antitumour activity by retarding the growth of HeLa-cell induced 
tumours in NOD-SCID mice151 and to enhance the chemotherapeutic effect of cispla-
tin in HeLa cells in vitro152. 
Molecular therapy based on cellular targets
Because inactivated tumor suppressor gene products such as p53 and p16INK4A are difficult 
to restore by molecular therapy, many studies have focussed on the identification of on-
cogenes and deregulated cell signalling pathways in HNSCC. Key pathways involved in 
HNSCC include EGFR, PI3K-PTEN-AKT, TGFβ and NF-κB signalling, for which inhibi-
tors are available, for example the anti-EGFR antibody cetuximab153, or being tested in 
several clinical trials (for reviews, see72,73).
In cervical cancer EGFR overexpression has been shown to negatively affect over-
all survival in patients treated with RT154. Anti-EGFR therapy using cetuximab lead to 
a therapeutic response in 12.5% of patients with uterine cervical SCC155. Also in HNSCC, 
including HPV-positive OPSCC, overexpression of EGFR correlates with poor progno-
sis67,70,71, although only a small subgroup of HPV-positive OPSCC exhibit EGFR protein 
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accumulation67,71. Large prospective trials with anti-EGFR therapy in HPV-positive HN-
SCC have been initiated97, although its efficacy is most probably limited to the small sub-
group of EGFR-expressing tumours. 
Alternatively, the PI3K-PTEN-AKT pathway might be an efficient target because 
HPV-positive OPSCC show extra copies of chromosome 3q in up to two-thirds of cases68, 
including the 3q26 locus, harbouring the PI3K gene. 
Tumor angiogenesis and metastases are correlated to upregulation of the TGF-β 
and NFκB pathways156,157. HPV positive OPSCC have been shown to metastasise in an 
earlier stage compared to HPV negative OPSCC158, indicating earlier endothelial-to-
mesenchymal transition (EMT), which is characterised by the expression of vimentin, 
dowregulation of E-cadherin and upregulation of β-catenin159. This suggests that EMT 
might be related to upregulation of these pathways and that particularly HPV-positive 
OPSCC might be a potentially interesting group for NFκB-inhibitors, for which a clinical 
trial has recently started160. 
Increased degradation of cell cycle regulatory proteins p53 and pRb by the on-
coproteins E6 and E7, can be inhibited by targeting the proteasomal pathway. Ritonavir, 
a protease inhibitor (PI) that is used in HIV-infected patients, inhibits the chemotryp-
tic activity of the human cellular 20S proteasome while increasing the tryptic activity161, 
resulting in reduced protein degradation. It was shown to enhance antitumour activity 
when combined with RT both in vitro and in vivo in a Hep-2 head and neck carcinoma 
model161, later however shown to be contaminated with Hela cells. The PI Lopinavir was 
shown to restore p53 expression and to induce apoptosis in SiHa cells162. Athough several 
clinical trials have evaluated the effectiveness of PIs in the treatment of HIV, clinical trials 
in the treatment of HPV-related disease have not been initiated. 
Finally, replication of the HPV virus can be targeted. In episomal HPV infection, 
replication is initiated by binding of E2 to its origin of replication54. In human transcrip-
tion factors the most commonly found DNA binding motifs are zinc fingers. Recently, 
artificial zinc fingers (AZF) have been developed as a potent new inhibitor of HPV163. 
When linked to a cell-penetrating peptide (CPP) these AZF were shown to inhibit HPV-
18 for 97%164. However, since the CPP-AZF are designed to prevent E2 from binding to 
its origin of replication, they are only effective in episomal HV infection. 
Discussion
The past decade has provided evidence for a  biological association between oncogen-
ic HPV and OPSCC. HPV-induced OPSCC show molecular and clinical features that 
are clearly different from tobacco- and alcohol-induced tumours and these differences 
seem to underlie prognostic differences between both tumor subgroups. Independent of 
treatment modality, patients with HPV-positive tumours demonstrate up to 30% better 
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survival rates. In the past decennia intensification of treatment was the most important 
strategy to improve survival of patients with HNSCC. However intensification of treat-
ment, combined with increased side effects, is finally reaching the maximum tolerance 
of the patient and this limits the intensity of treatment. Until now, no differentiation 
of therapeutic strategies is made between the HPV-positive and –negative subgroups in 
international guidelines on OPSCC treatment81. Because of the clinical and molecular 
differences between both groups the question arises whether HPV-positive tumours need 
equally intensive treatment protocols as their HPV-negative counterparts. Moreover, ad-
ditional antiviral therapeutic strategies can possibly improve survival without increasing 
therapy-related morbidity in HPV-positive tumours. In current and future studies we 
should therefore aim at improving the quality of life in patients by de-intensification regi-
mens in selected cases. Next-generation treatment strategies for HPV-associated cancers 
should focus on decreasing adjuvant radio- and chemotherapy, whether or not combined 
with therapeutic options specifically targeting HPV. Assessing which therapy is most ef-
fective will finally lead to a more personalised approach for individual patients. 
Immunomodulating therapies like IFN therapy seem to have beneficial effects, 
but this seems to be limited to episomal infections. This conveys the need to reliably 
establish the integration status of HPV infection. That this criterion has not yet been 
met becomes apparent when observing the reported integration frequencies, which range 
from 0 to 100%, depending on the population studied and methods used41,42. 
Tumor-specific host responses could also be enhanced by depletion of CD4+/
CD25+ regulatory T-cells (Tregs). Increased expression of Tregs was shown in patients with 
CIN and cervical cancer165,166. It is hypothesised that the enlarged population of Tregs sup-
presses HPV-specific immunity and inhibits tumor-specific T-cell responses. Upregulat-
ed Tregs have already been depleted using an anti-CD25 antibody, such as PC61167.
Other immunomodulating therapies such as imiquimod, a  topical immune re-
sponse modifier that has successfully been used in the treatment of anogenital lesions 
with episomal HPV infections168, are thought to be unsuitable for application in HPV-
related HNSCC and RRP. Application to cutaneous epithelia is known to induce local 
inflammatory responses and pain, which will be enhanced in mucosal epithelia. More-
over, the substance cannot be controlled to reach all tumor parts when topically applied, 
and, like IFN-therapy, will at best lead to eradication of only episomal HPV infections, 
whereas a large proportion of HPV-positive HNSCC show viral integration169. 
Antiviral therapies such as cidofovir and RNAi have already shown promising 
results and are expected to have progressive impact on the treatment of HPV-associated 
lesions. Cidofovir has been tested in cervical cancers and RRP, where it has been applied 
topically or intralesionally in most studies. It has been shown that combining IFN therapy 
with cidofovir could enhance the antiviral and antiproliferative effects of either substance 
alone, and it is postulated that adding IFN therapy could further improve the auspicious 
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effects of cidofovir combined with CT and/or RT170. Furthermore, it is recommended 
to assess the effects of cidofovir as adjuvant therapy in the treatment of HPV-associated 
HNSCC in a larger, prospective clinical trial. 
RNAi treatment, although tested in mouse models, has not yet been evaluated for 
use in human HPV-associated HNSCC. Such studies can, however, be expected in the 
near future, judging from patents referring to the use of oligonucleotides in the treatment 
of HPV infections (see for example171). 
Therapeutic approaches based on the molecular profile of the tumours are emerg-
ing in an adjuvant setting. However, one of the major drawbacks of such an approach is 
that the applicability should be assessed for each individual patient. For example cetux-
imab can only be applied in a small subgroup of patients with HNSCC, since HPV-pos-
itive tumours tend to show a low EGFR expression. In the current practice Cetuximab is 
already used for larger, non-resectable head and neck tumors, irrespective of HPV status. 
With regard to PIs and AZFs, no clinical studies have yet tested the applicability of these 
therapeutic options in the treatment of HPV-related carcinomas. 
Since therapeutic vaccination is expected to have minimal side effects it can be 
combined with other therapeutic approaches, such as RT and/or CT, to obtain synergistic 
effects. However, therapeutic vaccines are still in a developmental stage.
Although a significant reduction in the burden of HPV-related diseases can be 
anticipated if prophylactic vaccination will live up to its promises, only HPV-naïve fe-
males are currently vaccinated. We firmly believe that young HPV-naïve boys should also 
be vaccinated in order to achieve optimal protection, although it needs to be validated 
whether vaccination is cost-effective. 
In conclusion we can state that, although is has become evident that HPV-positive 
HNSCC have a better prognosis that their HPV-negative counterparts, the choice of ther-
apy for these two subgroups of HNSCC will strongly depend on the outcome of ongoing 
clinical trials, including de-intensification protocols and implementation of treatment 
options based on new insights into the molecular biology of HPV-infection. 
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Abstract
Objectives/Hypothesis: Assessment of the prognostic value of nodal status in relation 
to human papillomavirus (HPV) status and the various treatment modalities in tonsillar 
squamous cell carcinomas (TSCC). 
Study design: Retrospective 5-year survival analysis. 
Methods: A  5-year follow-up of disease-free, disease-specific, and overall survival in 
a group of 81 patients with TSCC was conducted. The nodal status and integration of 
HPV-DNA in the genome (detected with fluorescence in situ hybridization) as prog-
nostic indicators were examined while correcting for other clinical parameters (smoking 
habits, alcohol consumption, treatment modality, differentiation, TNM classification). 
Results: Of TSCCs, 41% were positive for HPV type 16. In these TSCCs, the primary tu-
mor was significantly smaller when compared to HVP-negative TSCCs (P = 0.04), where-
as the percentage of cases with cervical metastases was identical. In the total population, 
it was not nodal involvement, but rather HPV manifestation, which was related to patient 
prognosis. Within the treatment modalities (surgery combined with radiotherapy and 
radiotherapy alone), neither nodal status nor HPV were prognostic indicators. 
Conclusions: Since a substantial percentage of TSCCs are HPV-positive and metastasizes 
to cervical lymph nodes in less advanced primary tumors, the N status is an unreliable 
prognostic indicator in TSCCs. HPV is only prognostically relevant in the total tumor 
population, but loses its value within patient groups receiving a single treatment modal-
ity. The value of HPV for prognosis of patients with TSCC requires further study. 
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Introduction
During the past decades numerous investigations have shown an etiologic relationship 
between oncogenic or high-risk human papillomavirus (HPV) and squamous cell car-
cinomas of the tonsil (TSCC)1-4. The incidence of HPV in TSCC is increasing, possibly 
related to changes in sexual behavior, and ranges from 20% to 80% in different studies 
depending on the detection approach used5-8. There is increasing evidence that the patho-
genesis of HPV-positive tumors is different from their HPV-negative counterparts, which 
is confirmed by molecular and clinical differences between the two subgroups. Therefore, 
a different clinical approach may be advisable for both TSCC groups2-4,7,9. Weinberger et al. 
proposed a model for the development of HPV-positive carcinomas, in which three classes 
are differentiated and divided into two arms9. In the first arm, tumorigenesis is induced 
by alcohol consumption and/or smoking tobacco (class I). In this group, HPV superin-
fection of the tumor site may occur, resulting in an HPV-positive tumor with biological 
features that resemble alcohol/tobacco-related tumors (class II). In the second arm, the 
inducer of tumorigenesis is HPV (class III), independent of smoking tobacco and alcohol 
consumption. Many studies suggest a better prognosis for patients with HPV-associated 
head and neck carcinomas7, as a consequence of an improved response to treatment when 
compared to HPV-negative tumors10,11. Therefore HPV testing has recently been proposed 
to be included in the standard diagnostic work-up for oropharyngeal carcinomas8-10. 
Another factor influencing prognosis is tumor spread to cervical lymph nodes. 
For head and neck tumors in general, a  positive N status is considered the most reli-
able prognostic marker for an unfavorable prognosis12-14. However, TSCC literature is 
not consistent in confirming the prognostic value of N status15-17. The present study aims 
to examine the prognostic value of N status in a series of 81 TSCCs, while also taking 
into consideration the HPV status, clinicopathological features (age, gender, TNM clas-
sification, tumor differentiation grade, smoking tobacco, and alcohol consumption), and 
treatment of the tumor.
Materials and Methods
Tumor material and patient data
The study population consisted of 81 TSCC patients (mean age, 58.9 yrs; range, 39–87 
yrs; 73% male), 2 diagnosed between 1992 and 2001 at the Maastricht University Medi-
cal Centre, The Netherlands. The formaldehyde-fixed, paraffin-embedded archival bi-
opsy and resection materials of these patients have been classified by histopathology at 
the Department of Pathology and analyzed for the presence of oncogenic HPV16 DNA 
by means of polymerase chain reaction, fluorescence in situ hybridization, and p16 im-
munostaining.17 Data on age, gender, TNM classification, tumor differentiation grade, 
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smoking habits, amount of alcohol consumption, treatment modality, and follow-up were 
collected from the head and neck tumor database of our institute and from reviewing 
clinical, pathological, radiological, and surgical reports. Tumors of patients treated before 
1997 were reclassified according to the 1997 International Union Against Cancer classifi-
cation. Data on tumor differentiation grade were unavailable for three patients. 
Patients were classified as smokers (≥ 1 cigarette, pipe, and/or cigar per day) (n = 69) 
or nonsmokers (n = 12). The latter group consisted of patients who had never smoked 
(n = 10) and former smokers (n = 2), who had stopped smoking more than 10 years before 
diagnosis of TSCC. Patients were also classified as drinkers (consumption of > 2 whiskey 
equivalents of ≥ 10 g alcohol per day) or nondrinkers (0–2 whiskey equivalents per day). 
All patients were treated irrespective of their HPV status by multimodal regimens includ-
ing local resection, combined resection: neck dissection plus local resection, i.e., tonsil-
lectomy or combined mandibular operation (command-procedure), radiotherapy (RT), 
local resection plus radiotherapy, combined resection plus radiotherapy (CR/RT), che-
motherapy, or chemotherapy in combination with previous other treatment modalities.
Patients with tumors feasible for resection without unacceptable compromising 
organ functionality were treated with radical resection and elective neck dissection and 
postoperative radiotherapy if indicated. In patients who were primarily treated with radio-
therapy, the neck was also treated with radiotherapy. During multidisciplinary counselling, 
treatment plans were designed dependent on tumor size, neck staging, presence of distant 
metastases, feasibility of surgery, histopathology of resection specimens, clinical condition 
and comorbidities. With the exception of microcarcinomas, elective treatment of the neck 
was performed routinely, including in the N0 neck, because of the high incidence of occult 
metastases in TSCC 14,18-20. For patients treated with radiotherapy alone, histopathological 
data from surgical neck dissection were consequently unavailable. Therefore clinical stag-
ing (including panendoscopy, magnetic resonance imaging of the neck, ultrasound with 
fineneedle aspiration, and x-thorax) was used in this study. In the CR/RT group, there was 
one patient with a N0 neck according to diagnostic work-up, where a positive lymph node 
was observed in histopathological analysis after ipsilateral elective neck dissection. This pa-
tient was considered as N0 in this study. Follow-up data were collected with a minimum of 
5 years after treatment for all patients. The investigation was conducted in accordance with 
the declaration with the declaration of the World Medical Association in Helsinki in 1964 
and the subsequent revisions. The study protocol was approved by the institutional ethical 
committee. Written consent was obtained from all the patients included in this study. 
Statistical analysis
The association of N status and HPV status with other factors associated with progno-
sis, including age at time of diagnosis, gender, TNM status, tumor differentiation grade, 
smoking habits, and amount of alcohol consumption, were analyzed by cross-tabulations 
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using the 2-tailed χ2 test or 2-tailed Fisher exact test adhering to a significance level of 
P ≤ .05. Survival curves for disease-free survival (DFS), disease-specific survival (DSS), 
and overall survival (OS) were calculated using the Kaplan-Meier method21. Five-year 
survival was calculated from the date of diagnosis until death or until discharge from 
follow-up. DFS was calculated from the date of diagnosis until the date of recurrence 
(local, regional, or distant). Patients without recurrence were censored at the date of the 
last follow-up or the date of death. Differences between survival times were determined 
by the log-rank test in univariate analyses (significance level of P ≤ .05)21. Four patients 
initially presented with distant metastases and were excluded from the survival analysis.
Multivariate analyses were performed using the Cox proportional hazards model. 
Variables included were HPV, smoking tobacco, alcohol consumption, and T classifica-
tion. The inclusion of treatment modality as a variable depended on the number of pa-
tients within each treatment group. Variables remained in the model if their p-values 
were below 0.1017. SPSS version 12.0 software (SPSS Inc., Chicago, IL) was used for the 
statistical analysis.
Results
N Status and HPV status in relation to patient characteristics
A positive N status, as determined in the diagnostic work-up by clinical investigation and 
radiology, was more frequently observed in non- and former smokers (p = 0.048). Other 
clinicopathological factors (age, alcohol consumption, TNM-stage, and tumor differenti-
ation grade) and HPV status did not appear to be associated with N status (table 1). HPV 
status, however, correlated with a  poor tumor differentiation grade (p = 0.015), as did 
less or no smoking of tobacco (p = 0.011) and alcohol consumption (p = 0.003) (table 1). 
Primary tumor size at time of presentation was found to be significantly smaller in the 
HPV-positive group than in the HPV-negative group (p = 0.041) in spite of comparable 
frequencies of nodal involvement in both groups. Moreover, in the case of nodal involve-
ment, a swelling in the neck was the main reason for visiting the ENT outpatient depart-
ment for 15 of the 24 patients with HPV-positive TSCC, compared to only six of the 
30 patients with HPV-negative TSCC (p = 0.001).
N status and HPV status in relation to patient treatment
The different treatment modalities for TSCC are listed in table 2. The two largest patient 
groups receiving a single treatment modality included 30 patients treated with CR/RT 
and 30 patients receiving RT. The other treatment modalities were not taken into consid-
eration in this analysis because of the limited number of patients in these groups. 
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Table 1. N-status, HPV-status and treatment modality in correlation to patient characteristics.
N0 N+ p-value HPV+ HPV- p-value CR/RT RT p-value
Male/female 19 vs. 8 38 vs. 16 NS 24 vs. 9 31 vs.15 NS 20 vs. 10 24 vs. 6 NS
Age (mean) 56.9 59.1 NS 59.3 57.85 NS 58.53 56.4
range years 41-77 39-87 39-79 41-87 39-74 44-74
Smoking
Non-smoker/former smoker 
>10yrs.
2 14 0.048 11 5 0.011 11 1 0.001
Smoker 25 40 22 43 19 29
Alcohol
None/social 12 26 NS 22 16 0.003 14 13 NS
>2U/day 15 28 11 32 16 17
TNM
T1,2 vs. T3,4 12 vs. 15 26 vs. 28 NS 20 vs. 13 18 vs. 30 0.041 21 vs. 9 8 vs. 22 0.001
T1 3 6 3 6 4 2
T2 9 20 17 12 17 6
T3 12 15 9 18 8 11
T4 3 13 4 12 1 11
N0 vs. N+ / / / 9 vs. 24 18 vs. 30 NS 6 vs. 24 11 vs. 19 NS
N0 / / 9 18 6 11
N1 / / 6 11 7 7
N2 / / 16 14 17 7
N3 / / 2 5 0 5
M+ 0 4 NS 1 3 NS / / /
Tumor differentiation grade
poor 7 22 NS 17 12 0.015 11 10 NS
moderate/well 20 29 15 34 18 20
HPV16-status
positive 9 24 NS / / / 16 8 0.035
negative 18 30 / / 14 22
Local recurrence 8 2 0,002* 2 8 NS 0 6 0.024*
Regional recurrence 3 2 NS 1 4 NS 2 2 NS
Distant metastasis 1 3 NS 2 2 NS 1 3 NS
Total: 81 patients 27 54 33 48 30 30
P-values were obtained using 2-tailed χ²-test; asterisks indicate the use of Fisher exact test.
Abbreviations. CR/RT: patients treated with tumor surgery and neck dissection in combination with radio-
therapy; RT: patients treated with radiotherapy; NS: no significance detected (p-value > 0.05).
Functionally resectable tumors were preferably treated with CR/RT, whereas patients 
with functionally irresectable tumors or other contraindications for surgery were treat-
ed with RT alone. T status was significantly lower in the CR/RT group than in the RT 
group (p  = 0.001), whereas nodal involvement did not differ (table 1). HPV-positive 
TSCC were more often treated with CR/RT (p = 0.035), whereas HPV-negative TSCC 
were more often treated with RT (p = 0.048). In the CR/RT group, all HPV-positive pa-
tients had a positive N status, whereas in HPV-negative patients significantly less nodal 
involvement was present (p = 0.003).
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Table 2. HPV in correlation with treatment. 
HPV+ HPV- Total
Local resection (LR) 0 1 1
Combined resection (CR) 3 3 6
LR/RT 3 2 5
CR/RT 16 14 30
Radiotherapy (RT) 8 22 30
Chemotherapy (ChT) 2 1 3
CR/RT/ChT 1 0 1
RT/ChT 0 3 3
None 0 2 2
33 48 81
Patients treated with CR/RT (resectable tumors) smoked significantly less than 
patients treated with RT (p = 0.001). Smoking habits observed in both treatment modality 
groups were HPV-dependent. Nine of the 16 HPV-positive patients who were treated with 
CR/RT were nonsmokers, whereas the eight HPV-positive patients treated with RT (irre-
sectable tumors) all smoked (p = 0.007). In patients with HPV-negative tumors, no signif-
icant differences in smoking habits were found between the treatment modality groups. 
Alcohol consumption did not differ between treatment modality groups. Patients treated 
with CR/RT had a far more favourable 5-year overall, disease-specific, and disease-free 
survival compared to patients treated with RT (log-rank p < 0.001). This outcome based 
on patient treatment did not differ between the HPV-positive and HPV-negative patients 
with TSCC (OS, DSS, log-rank p < 0.001; DFS, log-rank p = 0.001). Moreover, in both 
treatment modality groups, there were no differences noted for the development of local 
and regional recurrence or for development of distant metastasis between HPV-positive 
and HPV-negative patients with TSCC (Fisher exact test).
N status and HPV status in relation to outcome
Nodal involvement did not correlate with survival in either the entire group of TSCC (fig-
ure 1A–C) or in the treatment subgroups CR/RT and RT. Remarkably, a trend for a favor-
able 5-year DFS rate was observed in patients with a lymph node metastasis (p = 0.067) 
(figure 1C). A statistically significant difference between the prognosis of HPV-positive 
and HPV-negative TSCCs was not found in the univariate analysis. However, there was 
a trend for a better DSS in the HPV-positive group (logrank p = 0.094) (figure 2A–C). 
Also within the treatment subgroups CR/RT and RT, HPV status proved to be an unreli-
able prognostic indicator. The influence of N status on prognosis was also analyzed in pa-
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Figure 1
(A) N status-dependent 5-year overall survival, p= NS
(B) Five-year disease-specific survival, p=0.NS
(C) Five-year disease-free survival, p=0.060
(Kaplan-Meier, log rank)
Figure 2.
(A) (HPV)-dependent 5-year overall survival, p=NS
(B) Five-year disease-specific survival, p=0.084
(C) Five-year disease-free survival, p=NS
(Kaplan-Meier, log rank)
A
B
C
A
B
C
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tients with HPV-positive and HPV-negative TSCC. In the HPV-negative group, the pres-
ence of nodal involvement seemed to be related to an unfavorable 5-year OS, DSS, and 
DFS rate (figure 3). In the HPV-positive group, however, the presence of nodal involve-
ment seemed to be related to a better OS, DSS, and DFS. In multivariate analysis neither 
N-status, nor gender, age and tumor differentiation grade appeared to have a statistically 
significant influence on survival. For HPV-negative TSCCs a 2 times higher risk of cancer 
death was found (95% confidence interval [CI ]. = 0.9–4.2) compared to patients with 
HPV-positive tumors. Patients with a tumor staged T3 or T4 had a 2.6 times increased 
risk of cancer death (95% CI = 1.4–4.9) compared to patients with tumor staged T1 or T2. 
However, the strongest prognostic factor was smoking; smokers had a 5.5-fold higher risk 
(95% CI = 1.3–23.6) of dying from cancer when compared to nonsmokers.17 Multivariate 
analysis within treatment modality groups CR/RT and RT were not performed due to the 
limited number of patients in each of these groups (n = 30).
Discussion
In head and neck squamous cell carcinoma (HNSCC), N status is known to be an impor-
tant prognostic factor. Nodal involvement reduces survival by more than 50% in patients 
with HNSCCs22-27. However, in recent years the prognostic value of nodal involvement in 
TSCC is becoming increasingly controversial15-17. A possible explanation for this finding 
is the heterogeneity in etiological factors underlying tumorigenesis in different head and 
neck mucosa areas. For example, HPV appears to play a much more prominent etiologi-
Figure 3
A)  N status-dependent 5-year disease-specific survival in patients with human papillomavirus (HPV)-positive tonsillar 
squamous cell carcinomas (TSCCs). 
B)  N status-dependent 5-year disease-specific survival in patients with HPV-negative TSCCs
(Kaplan-Meier, log-rank). NS = not significant. 
A B
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cal role in TSCC than in other head and neck tumors28,29. Moreover, the incidence of HPV 
in TSCC has increased substantially in the past few decades5-8. Therefore, investigation 
into whether the presence of HPV underlies the decreased prognostic value of nodal in-
volvement in TSCC is warranted. In our study we noticed that the only clinical parameter 
associated with a positive neck status in TSCCs was absence of tobacco smoking. This pa-
rameter, however, was found to correlate much stronger with the presence of HPV in the 
tumor (41% of cases). This observation has also been described in other studies7-9. Ad-
ditional parameters correlating to HPV included less or no alcohol consumption, a poor 
tumor differentiation grade, and a smaller T stage.
The latter finding suggests a  different tumor biology for HPV-positive TSCCs 
with regional spreading occurring at smaller primary tumor sizes. Possibly, HPV-positive 
tumors were detected in smaller T stages because of an earlier clinical presentation of 
a lymph node metastasis in this group. We observed a relationship between a swelling in 
the neck as presenting symptom and the presence of HPV in the primary tumor. This has 
also been described in literature17. This pattern of regional tumor spreading in smaller 
primary tumor sizes may contribute to an earlier detection of a so far unknown primary 
tumor at a smaller size. According to this hypothesis, the tumor biology of HPV-positive 
tumors would result in the detection of tumors with smaller T stages. In this study pa-
tients with tumors feasible for resection with respect to organ functionality were treated 
with CR/RT, and (functionally) inoperable tumors were treated with RT. As a  conse-
quence, the CR/ RT group showed a significantly better outcome. Because of their smaller 
primary tumor sizes, HPV-positive TSCCs were more often feasible for resection and 
subsequently more often created with CR/RT. We would like to stress that conclusions 
with respect to the efficacy of these treatment modalities should not be extracted from 
the data presented here. To what extent patient-dependent factors such as life style and 
comorbidities influence clinical choice and treatment outcome remains to be studied. 
A favorable performance status appears to be related to HPV-positive tumors11. The in-
verse relation between tobacco smoking, alcohol consumption, and HPV-status suggests 
also that the difference in life style may result in a decreased prevalence of comorbidities 
in the HPV-positive tumor population.
N status was not found to be of prognostic value in TSCC. Patients with HPV-
negative TSCC were found to have a 2 times greater risk of cancer death. Separate analysis 
of the CR/RT and RT groups did not indicate that these two parameters had an effect 
on prognosis. HPV-positive tumors, thus, show no significant improvement of response 
to therapy within the different modality groups. Although this could be caused by the 
relatively limited number of patients in the different treatment groups, a  recent study 
also showed no significantly favorable prognosis of HPV-positive oropharyngeal tumors 
when treated with combined radio/ chemotherapy11. Multiple hypotheses for a  better 
outcome of HPV-positive tumors have been put forward. They are all based on factors 
related to therapy-outcome: absence of field cancerization as a consequence of the in-
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verse relation of HPV and tobacco smoking and alcohol consumption, an intact apop-
totic tumor response to radiation, and an immune surveillance to viral-specific tumor 
antigens30-33. However, in most cases multimodal treatment modalities have been used. In 
our study, the presence of nodal involvement in HPV-negative TSCC seemed to expose 
a negative influence on the prognosis. However, in HPV-positive TSCC nodal involve-
ment even appeared to ameliorate outcome. This suggests that the tumor biology of HPV-
positive TSCC is not only different from the HPV-negative TSCC, but also has a great 
influence on the clinical presentation and outcome. As mentioned, nodal involvement 
in HPV-positive TSCCs is often the presenting symptom and seems to indicate the pres-
ence of a  smaller primary tumor in HPV-positive TSCCs (squealer node in unknown 
primary tumors). Subsequently, these HPV-positive TSCCs are more feasible for a radical 
therapeutic approach. This indicates that the outcome of HPV-positive tumors is not only 
dependent on a better response to different (multimodal) treatment modalities, but more 
importantly, the presence of HPV in TSCCs seems to determine the choice of treatment 
as a result of its biology. As a consequence of the controversial prognostic value of nodal 
involvement, we advise the implementation of testing HPV diagnostically to stratify in 
TSCC tumor staging.
Conclusions
HPV-positive tumors, which are associated with less smoking and alcohol, have a differ-
ent tumor biology. They have smaller primary tumor sizes, although regional lymph node 
involvement is comparable to HPVnegative tumors. Our data indicate that the relatively 
favorable prognosis of HPVrelated TSCC is determined by the choice of treatment as a re-
sult of its biology. The prognostic value of nodal involvement is reduced by the presence of 
HPV. HPV testing in the diagnostic work-up is therefore advised in TSCC tumor staging.
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Abstract
Infection with human papillomavirus (HPV) type 16 is an independent risk factor for the 
development of oropharyngeal squamous cell carcinomas (OPSCC). Although integra-
tion of HPV16 DNA into the human genome has been shown to play an important role 
in anogenital and particularly in uterine cervical carcinogenesis as well as tumor progres-
sion, this association is still largely unclear for OPSCC. Integration is mostly determined 
by PCR-based methods or in situ hybridization. However, reported HPV integration fre-
quencies for OPSCC vary greatly and fluctuate between 0% and 100%, which might be 
due to the applied methods. 
We have evaluated 75 patients with OPSCC for the physical status of HPV16, 
i.e. episomal versus integrated, using two independent techniques to detect virus-human 
fusion sites, i.e. PCR amplification of papillomavirus transcripts (APOT-PCR) and detec-
tion of integrated papillomavirus sequences by ligation mediated PCR (DIPS-PCR). 
HPV16 integration in the cellular genome was identified in approximately 40 % 
of OPSCC. HPV integration sites were distributed over the genome, with a preference for 
gene loci reported to be involved in tumorigenesis and including BCL2, FANCC, TRAF3 
and TP63. Integration was detected in both exon and intron sequences, as well as in sense 
or antisense orientation of the reported genes. Half of the integration sites were found in 
the proximity of reported fragile sites. 
These data indicate that HPV16 integration is not a prerequisite for tumorigenesis 
of OPSCC, but in case of integration this often occurs in transcribed regions and espe-
cially in genes with reported involvement in tumorigenesis. 
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Introduction
Approximately 600.000 new cases of head and neck squamous cell carcinoma (HNSCC) 
have been estimated to occur worldwide in 2011, ranking them in sixth position of all 
carcinomas1-3. Disappointingly, even with the implementation of multimodal therapies, 
limited progress has been made in the last decades with respect to disease-free survival or 
5-year survival rates, which are currently 50% - 60% for new HNSCC patients3,4. 
Risk factors for the development of HNSCC include environmental factors, ex-
cessive tobacco- and alcohol use, as well as HPV infections. Particularly oropharyngeal 
squamous cell carcinomas (OPSCC) show high infection rates, with up to 50% of the tu-
mors being HPV-positive, mainly HPV type 16. HPV-positive tumors tend to show clini-
copathological and molecular characteristics that are different from those of patients with 
tobacco- or alcohol-induced tumors5-7. The reported prevalence of HPV-related OPSCC, 
however, varies broadly amongst several studies due to differences in the study popula-
tion, combination of histological subsites, type and number of specimens analyzed, and 
detection methods used. 
It has been shown for anogenital carcinomas, in particular uterine cervical car-
cinomas, that integration of viral DNA into the host genome directly correlates to the 
progression from dysplastic lesions to carcinomas in most of the cases8,9. Integration of 
HPV DNA appears to be a direct result of chromosomal integrity destabilizing processes 
mediated by the expression of viral oncogenes E6 and E7 and seems to occur relatively 
late in the progression of anogenital dysplasia. In the anogenital region, almost 200 in-
tegration sites have been mapped, which showed to be unique, and involved all chro-
mosomes although some clusters of integration could be identified, for example in the 
cytegenetic bands 4q13.3, 8q24.21, 13q22.1 and 17q218,10-12. Preferred sites for integra-
tion proved to be fragile sites, translocation break points, and transcriptionally active 
regions. Even though many similarities are seen between uterine cervical carcinomas and 
HPV-induced HNSCC, the almost exclusive infection with HPV16 in HNSCC may in-
dicate differences in tumorigenic mechanisms. In addition, high variation in integration 
frequency have been reported in HNSCC, ranging from virus being present only in an 
episomal form to 100% integrated, depending to the techniques applied to determine 
integration status6,13-15. This confers the need for a more detailed analysis of integration 
frequencies and characterization of integration sites. It has already been shown for HN-
SCC that HPV can integrate16,17 but we are the first providing integration data for a cohort 
of 75 HPV-positive OPSCC with two methods that give direct information about the 
viral-human fusion site, namely APOT-PCR- and DIPS-PCR. In conclusion, our data 
showed that HPV16 could only be found in episomal state in the majority of OPSCC 
and integration is therefore not a necessity for carcinogenesis. On the other hand, when 
integration does occur, transcribed regions and especially gene with known involvement 
in tumorigenesis were detected. 
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Materials and methods
Subjects and Material
Clinical samples were collected from patients treated at the the departments of otorhi-
nolaryngology, head and neck surgery of the University hospitals of Cologne and Maas-
tricht between 1994-2009. Written informed consent was obtained from all patients. 
From a total of 75 patients fresh frozen tumor tissue, preserved in liquid nitrogen, was 
analyzed. Inclusion criteria were the availability of sufficient fresh frozen tumor tissue 
containing ≥ 70% tumor cells, with sufficient and high quality tumor DNA and RNA 
as well as active infection with HPV16, as shown by the presence of HPV DNA18 and 
overexpression of the surrogate marker p16INK4A, as previously reported19,20. 
Patient age ranged from 44–83 years (median 62.7 years). Fifty-seven (76.0 %) 
patients were male and eightteen (24.0 %) patients were female. 
Immunohistochemistry for p16INK4A
Immunohistochemical staining was performed on corresponding 5 µm-thick formal-
dehyde-fixed, paraffin-embedded tissue sections. Sections were stained as previously 
described by Wittekindt et al.21. Briefly, monoclonal mouse anti human p16INK4A anti-
body, clone E6H4, CINtec Histology Kit (MTM Laboratories AG, Heidelberg, Germa-
ny) was used as the primary antibody. Immunohistochemical detection was performed 
by the avidin-biotinylated peroxidase complex (ABC) procedure (Vectastain-Elite-
ABC kit; Vector) or PowerVision (Leica Biosystems Newcastel Ltd, Newcastle, UK). 
Peroxidase activity was detected using diaminobenzidine/H2O2 (BD Biosciences, Hei-
delberg, Germany). Sections were counterstained with hematoxylin and mounted in 
mounting medium. Each analysis included negative and positive controls. 
PCR
DNA was isolated from fresh frozen tumor material using QIAGEN Gentra Puregene Tis-
sue Kit (Cologne) or QIAgen DNA Blood Mini Kit (Maastricht), as per the manufacturers 
instruction (Qiagen, Hilden, Germany). The presence of HPV DNA was detected using 
a higly sensitive group-specific nested PCR with degenerate primers A5/A10 and A6/A8 
(268 bp product)18. Five μl of PCR product were separated on a 1.5 % agarose gel and visu-
alized using ethidium bromide staining. When HPV DNA was detected, HPV typing was 
performed, either by direct sequencing (Cologne) or by type-specific PCR (Maastricht). 
In addition, β-globin gene PCR served as a positive control for sufficient DNA of 
adequate quality and to show that sample were free of PCR inhibitory substances (268 bp 
PC04/GH20 PCR product)22.
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Amplification of Papillomavirus Oncogene Transcripts PCR (APOT-PCR)
Total RNA was extracted from five 10 µm-thick snap frozen tissue sections, using 
the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s in-
structions, including DNase treatment. RNA concentration and quality were deter-
mined by RNA standard sense chips on a BioRad Experion system (BioRad, Munich, 
Germany). HPV oncogene transcripts were amplifed as described before23. Briefly, 
reverse transcription was performed using 25 μM oligo-(dT)17 primer coupled to 
a linker sequence (dT)17-p3, 10 mM dNTPs each, 0.1 M DTT, 5x RT-buffer and Su-
perScript reverse transcriptase (Invitrogen, Karlsruhe, Germany)24. Quality of cel-
lular DNA was determined by a standard GAPDH gene PCR (441 bp product). First-
strand cDNAs containing viral oncogene sequences were subsequently amplified 
with semi-nested PCR using HPV-E7 specific 5’primers and oligo(dT) and adaptor 
primers (3’). PCR products were separated on a 1.2% agarose gel. Bands typical for 
integration were cut out, purified (QIAGEN Gel extraction kit, QIAGEN, Hilden, 
Germany) and sequenced (GATC Biotech, Konstanz, Germany). Sequence results 
were analyzed using the BLASTN program and further mapped using map viewer, 
both provided by the NCBI. 
Detection of Integrated Papillomavirus Sequences PCR (DIPS-PCR)
Integrated papillomavirus sequences were detected using the Detection of Integrated 
Papillomavirus Sequences-PCR (DIPS-PCR) assay, as described earlier11. Shortly, ge-
nomic DNA was digested using the Sau3AI restriction enzyme and an enzyme-specific 
adapter was ligated to the restriction-digested DNA using T4 DNA ligase (Roche Di-
agnostics, Mannheim, Germany). Linear PCR was performed using 5 HPV16 specific 
forward primers in independent setups, all using the same specific adapter primer 1 
(AP1). All independent PCRs were followed by individual exponential PCRs using fur-
ther virus-specific forward primers and the AP1 reverse primer. PCR products were 
separated on a 1.2% agarose gel and products of interest were excised and subsequently 
sequenced (GATC Biotech). Sequence results were analyzed using the BLASTN pro-
gram and further mapped using map viewer, both provided by the NCBI. 
Results
The integration status of the viral genome was analyzed using both an mRNA based 
3’-RACE PCR based on Klaes et al.23 (APOT-PCR, Amplification of Papilloma Virus On-
cogene Transcripts) as well as with a  ligation-mediated Detection of Integrated Papillo-
mavirus Sequences (DIPS-PCR) based on Luft et al.11. A preselected group of 75 patients 
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with OPSCC, known to harbour active HPV16 infection, was analyzed. PCR-products 
suspected to be derived from integrated HPV16 genomes were sequenced and compared 
with the human genome database using the BLASTN-program and further mapped us-
ing the Map Viewer, provided by the National Cancer Institute, USA. When viral-cellular 
fusion products were detected, HPV16 was considered to be integrated. 
A total of 29 OPSCC (38.7 %) showed integration with either DIPS-PCR and/
or APOT-PCR, whereas 46 samples only showed episomal PCR products (61.3%). Inte-
gration sites were found to be distributed throughout the genome, targeting most chro-
mosomes except chromosomes 11, 16, 19, 20, 21 and X (see figure 1), which supports 
previous findings in anogenital lesions that there is no preferred integration site for HPV 
in the human genome12,25. 
Analysis of the genomic integration locus using DIPS-PCR detected a  total of 
21 viral-cellular fusion products from 19 samples. As shown for anogenital lesions, we 
also found 3’disruption sites of the HPV genome to be different in all samples, ranging 
from nucleotide 1124 in the HPV16 E1 gene up to nucleotide 3351 in the HPV16 E2 
gene. A total of 13 disruption sites were found in the E1 gene and 8 were found in the 
E2/E4 gene. Integration events occurred in transcribed genomic regions in 14/21 cases 
(66.7%), whereas 7/21 (33.3%) integration products were mapped to intergenic regions 
Figure 1. Chromosomal distribution of viral integration sites. Integration sites were found all over the genome, except for 
chromosomes 11, 16, 19, 20, 21 and X. Integration sites are indicated on the right side of each chromosome and fragile sites 
that are located within 5 MB of the nearest integration site are indicated on the left side of the chromosome. Integration 
sites detected by APOT-PCR are indicated by red triangles, sites detected by DIPS-PCR are indicated by blue squares and 
sites detected by both methods are indicated by black filled circles. 
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without known reported genes. We found both integration into exons (5/14) as well as 
into introns (9/14) and integration occurred in sense (7/14) as well as in antisense (7/14) 
orientation of the genes. 
HPV oncogene transcripts could be amplified from 23 OPSCC samples, showing 
26 fusion transcripts. A total of 21 transcripts showed direct splicing from viral nucleo-
tide 880 into the cellular flanking sequence (Type A splicing as described by Klaes et al.23, 
figure 2). One transcript was spliced using the E4 splice acceptor site before splicing 
into the cellular flanking sequence (Type B splicing, figure 2). Four transcripts, how-
ever, showed so far undescribed splicing from viral nucleotide 880 to viral nucleotide 409 
(in the viral E6 gene) and subsequently to the human sequence (Type D splicing, figure 
2). One additional episomal sample showed similar splicing, from viral nucleotide 880 
to viral nucleotide 409, without evidence for integration. Most episomal viral transcripts 
are spliced regularly from nucleotide 880 to 3358, however, two cases of episomal HPV 
showed splicing from 880 to 2702 and 880 to 2707. 
Although most patients only show one integration site, using either APOT- and/
or DIPS-PCR, there are three patients that show more than one integration site. The high-
est number of integration sites found was 4, with 3 of them detected by DIPS-PCR. In 
addition, APOT-PCR was able to detect two fusion transcripts in this tumor, which were 
located in the same cytogenetic band with a distance of 43.2 kB (patient no. 1). However, 
the fusion transcript detected by APOT-PCR did not correlate to the DIPS-PCR integra-
tion sites. Two additional sample showed two independent splice products using APOT-
PCR, which proved to be in different chromosomes. 
Figure 2. Episomal and integration derived mRNA splicing types. Type A shows splicing from HPV E1 (nucleotide 880) to 
the cellular sequence. Type B shows HPV E1 spliced to HPV E4 and subsequently to the cellular DNA. Type C transcripts 
are not spliced (not observed in this study). Type D shows so far undescribed splicing from viral E1 to viral nucleotide 409 
and subsequently from viral E7 to the cellular sequence. Viral DNA is indicated as such, since it has not been sequenced. 
Adapted from Wentzensen et al.12 and Lace et al.16. 
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The presence of fragile sites was analyzed for all integration loci, and eightteen 
integration sites (48.6%) proved to be located within 5 Mb of the nearest fragile site. 
Of the cellular sequences that were found using either DIPS- and/or APOT-
PCR, 27 fusion products corresponded to a known or predicted gene (73%), whereas the 
remaining 10 sequences were located in intergenic regions (27%). For the (predicted) 
genes, 9 fusion sequences corresponded to introns and 5 to exons using DIPS-PCR and 
11 fusion transcripts corresponded to introns and 7 to exons using APOT-PCR. Further-
more, the viral sequences proved to be in sense orientation with the cellular sequences 
for only half of these genes. 
Of the 27 viral-human fusion products that were found to correspond to tran-
scribed regions, 12 fusion products matched known tumor-related genes (BCL2, BRE, 
EPHA7, FANCC (2x), HDAC2, INO80C, LEPREL1, SYNPO2, TP63, TRAF3, TUBD1) 
whereas an additional 5 fusion products matched genes involved in pathways that are 
reported to be compromised in tumors (ERC2, GARS, SLC7A1, SYN3, ZMAT4), as veri-
fied using the ATLAS of genetics and cytogenetics in oncogoly and hematology database 
26. The remaining 10 fusion products were not associated with any known or suspected 
tumor-related gene. Lastly, 3 integration events occurred into pseudo-genes. 
In 9 cases, the fusion products detected with DIPS- and APOT-PCR showed cor-
relation. In one additional case, the sequence obtained by APOT-PCR was located 20 MB 
downstream of the sequence detected by DIPS-PCR. In three cases the splice products 
used the natural splice acceptor sites for the human genome, whereas 7 products were 
spliced to a cryptic splice acceptor site. 
In 17 cases (16 carcinomas) the fusion products could only be detected by either 
APOT-PCR (11) or DIPS-PCR (6). Of the 11 cases (10 carcinomas) where APOT-PCR 
could detect a  fusion transcript, DIPS-PCR showed no detectable band in 6 cases and 
only an episomal band in 4 cases. Vice versa, in the 6 cases where DIPS-PCR could detect 
a viral-human fusion product, APOT-PCR showed no detectable band in 2 cases and 
detected 4 episomal bands. 
Finally, in five cases the results from APOT-PCR and DIPS-PCR did not correlate, 
as the fusion products originated from different chromosomes. 
Discussion
DNA based PCR methods, including DIPS- and APOT-PCR, can be used to determine 
the exact chromosomal location of viral integration sites. So far these methods have 
mainly been applied to determine HPV integration in anogenital lesions, reporting high 
integration frequencies8,9,12. In these studies it has been reported that HPV integration 
often leads to deregulated and enhanced oncogene expression, which suggests a major 
role for HPV integration in neoplastic transformation27,28. 
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For HNSCC there is much controversy in reported integration frequencies. De-
pending on the detection methods used to assess the viral physical status, both litera-
ture in favour of integration (FISH and PCR)6,14,15 as well as episomal cellular appearance 
(PCR)13 have been published. 
This study is the first reporting the exact chromosomal location of viral integra-
tion on a large cohort of HPV16-positive OPSCC tumors using DIPS- and APOT-PCR. 
We were able to identify a viral-cellular fusion product in 38.7% of the tumors indicating 
that HPV is maintained in an episomal state in the remaining tumors. 
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Although initial reports showed integration percentages of up to 88% by APOT-
PCR23, more recent studies analyzing integrated viral sequences using DIPS- or APOT-
PCR are in line with our findings as they showed integration percentages ranging from 
7.4% 29 using DIPS-PCR up to 55% using APOT-PCR9,30. Analysis of HNSCC using 
APOT-PCR showed integration ranging from 17%17 up to 66%16 of the HPV-positive 
samples. However, these studies analyzed only a small number of tumor-derived samples 
(12 and 9 respectively). 
In line with these previous reports, we have also found integration sites distrib-
uted all over the human genome, without obvious preferences for any cytogenetic region. 
However, for anogenital carcinomas some integration sites tended to cluster to defined 
cytogenetic bands. Based on the results of our study, we cannot confirm this pattern for 
OPSCC, although the total number of integration sites found in our cohort might not be 
sufficient to observe possible clustering. However, it is interesting to note that we have 
found integration loci on chromosomes 8q24.21, 13q22.1 and 17q21, which were re-
ported to harbour HPV integration clusters8. Furthermore, we found integration at 3q28 
containing the LEPREL1 gene, which was spliced to TP63. Kraus et al. also reported two 
integration loci in this same region. This might point to an additional site for HPV inte-
gration clustering, which could indicate direct influence of HPV integration on the TP63 
tumor suppressor gene. In addition, two independent integration events occurred in the 
FANCC gene located on 9q22.3. Alteration in this region have recently been reported to 
an early and frequent event in head and neck cancer development31. 
In our study, a total of 73% of integrated samples was found to be located in tran-
scribed regions, which is in agreement with previous studies8-11,23,25,32. It is well established 
that only 2% of the total human genome codes for transcribed sequences, and we agree 
with Kraus et al.8 that integration is therefore not an entirely random event, even though 
the found integration sequences are distributed all over the genome. This hypothesis is 
further underlined by the high percentage of integration in sequences that code for tu-
mor related genes. 
From the total of 75 samples, 21 (26.3%) integration sites were found using DIPS-
PCR and 26 (34.2%) were found using APOT-PCR. However, only 11 sites (14.5%) were 
found by both methods. Inconsistencies between DIPS- and APOT-PCR indicate that 
detection of integration-derived sequences might be influenced by the cellular environ-
ment and therefore could have missed integration events. These may include very long 
viral-cellular fusion products, high viral load, high viral gene expression, alterations of 
the HPV promotor, transcriptional silencing driven by cellular sequences and integration 
in head-to-tail tandem repeats. A combination of independant methods is therefore rec-
ommended for further studies to maximize the detection of viral integration. 
The so far undescribed splicing from viral E1 to E6 gene and subsequently from 
from viral E7 gene to human cellular DNA (figure 2) suggests that HPV is integrated in 
head-to-tail tandem repeats in these cases. 
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In two cases we have found integration sequences for both DIPS- and APOT-
PCR, however, the viral-cellular fusion transcript as detected by APOT-PCR turned out 
to be in opposite direction as compared to DIPS-PCR. In a  third case the integration 
sequences found by DIPS- and APOT-PCR were derived from the same chromosome, 
although the found loci were 20 MB apart. It has been shown that HPV DNA integration 
can lead to complex genomic rearrangements. Both rearrangement changing the orienta-
tion of the 5’- and 3’ cellular sequences flanking the viral integration site, as well as dele-
tions of larger genomic regions starting at the viral integration site have been reported33,34. 
Taken together, the relatively high number of integration sites in either genes or 
predicted genes suggests that the disruption or deregulation of specific genes through 
HPV integration could contribute to the process of transformation and carcinogenesis. 
However, since we have only detected fusion products in 39.5% of OPSCC, it is not likely 
that HPV16 integration is a necessary cause for tumorigenesis. 
In conclusion, we report integration in specific or predicted genes. This may have 
a direct effect on the gene itself but could also have effect on other cellular genes and path-
ways due to complex genomic alterations at the site of integration35. The (tumor-specific) 
effects of these alterations on the process of transformation and tumorigenesis should be 
systematically evaluated in ongoing or future studies. 
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Abstract
Infection with high-risk human papillomavirus (HPV) type 16 is an independent risk 
factor for the development of oropharyngeal squamous cell carcinomas (OPSCC). How-
ever, it is unclear whether viral integration is an essential hallmark in the carcinogenic 
process of OPSCC and whether HPV integration correlates with the level of viral gene 
transcription and influences the expression of disrupted host genes. 
We analyzed 75 patients with OSCC. HPV16-positivity was proven by p16INK4A 
immunohistochemistry, PCR and FISH. Viral integration was examined using DIPS- as 
well as APOT-PCR. Viral E2, E6 and E7 gene expression levels were quantified by real 
time (RT)-PCR. Expression levels of 7 human genes disrupted by the virus were extracted 
from mRNA expression profiling data of 32 OSCC. Viral copy numbers were assessed 
by quantitative RTPCR in 73 tumors. We identified 37 HPV16-human fusion products 
indicating viral integration in 29 (39%) OPSCC. In the remaining tumors (61%) only 
episome-derived PCR products were detected. When comparing OPSCC with or without 
an integration-derived fusion product, we did not find significant differences in the mean 
expression of viral genes E2, E6 and E7, nuclear FISH staining patterns or the viral copy 
numbers per cell, nor did the expression of the HPV-invaded genes differ from either 
group of OPSCC. In conclusion, our data do not support the hypothesis that integration 
affects the levels of viral and/or HPV-disrupted human gene transcripts. Thus constitu-
tive, rather than a high level, of expression of oncogene transcripts appears to be required 
in HPV-related OPSCC. 
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Introduction
Approximately 600.000 new cases of head and neck squamous cell carcinoma (HNSCC) 
have been estimated to occur worldwide in 2011, ranking them in sixth position of all 
carcinomas1-3. Risk factors for the development of HNSCC include environmental fac-
tors, excessive tobacco and alcohol use, as well as human papillomavirus (HPV) infec-
tions. Particularly oropharyngeal squamous cell carcinomas (OPSCC) are associated 
with HPV164. This group of carcinomas shows clinicopathological and molecular char-
acteristics that differ from alcohol- and tobacco-induced carcinomas4-6. Studies that have 
assessed the prevalence of HPV-induced OPSCC report frequencies ranging from 20% 
to up to 90%5,7-9. 
Although integration of the viral DNA into the host genome is not part of the nor-
mal viral life cycle, studies in anogenital carcinomas have shown a significant correlation 
between integration and progression of dysplastic lesions to invasive carcinomas10,11. For 
example in uterine cervical carcinomas, it has been shown that oncogene transcripts in-
dicating viral integration can be identified in 55% of HPV16 positive cases and 92% of the 
HPV18 positive cases, and that particularly for HPV16 the integration events have been 
found to occur already in cervical intraepithelial neoplasia (CIN)11. We recently also de-
tected viral integration in head and neck oropharyngeal dysplasia adjacent to squamous 
cell carcinoma by FISH, however these dysplasia are a rare finding in the oropharynx12. 
Using Amplification of Papillomavirus Oncogene Transcripts PCR (APOT-PCR), 
so far only two studies report HPV16 integration in 2 out of 4 and 6 out of 9 tumors in 
HPV-DNA positive OPSCC13,14.
However, there is controversy with respect to the relation between viral integra-
tion and viral gene expression. Integration of HPV DNA in uterine cervical squamous 
cell carcinomas (UCSCC) has been correlated to disruption of the viral regulatory gene 
E215,16. Studies in cell lines have shown that E2 represses the viral E6 and E7 expression17. 
In the uterine cervical cell line W12, integration of HPV was shown to result in higher 
levels of the oncogenes E6/E7 and a selective growth advantage over cells harboring ex-
trachromosomal HPV DNA18. This had led to the hypothesis that the levels of viral E6 
and E7 transcripts are higher in lesions in which viral integration resulted in E2 disrup-
tion, which is thought to lead to deregulation of cell cycle control19-21.
On the other hand, a study in primary keratinocytes immortalized with HPV16 
genomes has shown that disruption of the E2 gene sequence upon viral integration does 
not result in increased expression of the viral E6 and E7 oncogenes13. In addition, a pub-
lication by Häfner et al. using APOT-PCR has shown no correlation between the inte-
gration state of the viral genome and the expression of the viral gene E6 in a collection 
of 55 HPV16-positive cervical carcinoma samples22. It would be interesting to examine 
viral physical status and E2, E6 and E7 gene expression in primary OPSCC since this 
information is lacking. 
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Here we present the HPV16 integration status for a collection of 75 HPV16-DNA- 
and p16INK4Apositive OPSCC using APOT- and Detection of Integrated Papillomavirus 
Sequences PCR (DIPS-PCR), and its relation to the level of gene expression for the viral 
genes E2, E6 and E7, a number of human genes disrupted by viral integration and viral 
DNA-load. 
Materials and methods
Subjects and Material
Fresh frozen clinical OPSCC samples from 75 patients treated at the Departments of Oto-
rhinolaryngology and Head and Neck Surgery of the University Hospitals of Cologne and 
Maastricht between 1994 and 2009 were collected from the archives of the Departments 
of Pathology of both hospitals. Patient material was used according to the code for proper 
secondary use of human tissue. Inclusion criteria were the availability of sufficient fresh 
frozen tumor tissue containing ≥ 70% tumor cells, high quality tumor DNA and RNA and 
HPV16 infection, as detected by HPV-specific DNA analysis4,5,23,24 and overexpression of 
the surrogate marker p16INK4A as detected by immunohistochemistry25,26. 
Patient age ranged from 44–83 years (median 62.7 years). Fifty-seven (76.0%) pa-
tients were male and eighteen (24.0%) were female. 
Amplification of Papillomavirus Oncogene Transcripts PCR (APOT-PCR)
Total RNA was extracted from five 10 µm-thick snap frozen tissue sections using the 
RNeasy mini kit (Qiagen, Hilden, Germany) and DNase treatment. RNA concentra-
tion and quality were determined by RNA StdSens Chips on a BioRad Experion system 
(BioRad, Munich, Germany). HPV oncogene transcripts were amplified as described 
before27. Briefly, reverse transcription was performed using 25 μM oligo-(dT)17 primer 
coupled to a linker sequence (dT)17-p3, 10 mM dNTPs each, 0.1 M DTT, 5x RT-buffer 
and SuperScript reverse transcriptase (Invitrogen, Karlsruhe, Germany)28. Quality of 
transcribed cDNA was determined by a standard GAPDH gene PCR (441 bp product). 
First-strand cDNAs containing viral oncogene sequences were subsequently amplified 
with semi-nested PCR using HPV-E7 specific 5’primers and oligo(dT) and adaptor 
primers (3’). PCR products were separated on a 1.2% agarose gel. Both bands typical for 
episomal and integration status were cut out, purified using the QIAGEN Gel extraction 
kit (QIAGEN, Hilden, Germany) and sequenced (GATC Biotech, Konstanz, Germany). 
Sequence results were analyzed using the BLASTN program and further mapped using 
map viewer (both NCBI)29,30. 
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Detection of Integrated Papillomavirus Sequences PCR (DIPS-PCR)
Integrated papillomavirus sequences were detected using the Detection of Integrated 
Papillomavirus Sequences-PCR (DIPS-PCR) assay, as described earlier31. Briefly, ge-
nomic DNA was digested using the Sau3AI restriction enzyme and an enzyme-specific 
adapter was ligated to the restriction-digested DNA using T4 DNA ligase (Roche Diag-
nostics, Mannheim, Germany). Linear PCR was performed using 5 HPV16 specific for-
ward primers in independent setups, all using the same specific adapter primer 1 (AP1). 
All independent PCRs were followed by individual exponential PCRs using further virus-
specific forward primers and the AP1 reverse primer. PCR products were separated on 
a 1.2% agarose gel and products of interest were excised, purified, sequenced and ana-
lyzed as described before. 
Gene expression analysis
mRNA Expression Profiling
Total RNA was collected from a  subset of 32 samples, randomly selected from the 
75 patients in this study. Samples were analysed using Agilent Whole Human Genome 
4 x 44K Microarrays, which represent more than 41,000 unique human transcripts. La-
belling and hybridizations were performed according to the manufacturer’s instructions 
(Agilent Technologies). Hybridized arrays were scanned using an Axon GenePix 4000B 
or 4200A scanner. Microarray analysis was performed using GenePix Pro 6.0.1.25. For 
normalization processing, the median array intensity was calculated based on the back-
ground-subtracted intensity value for all spots excluding control type spots on the array. 
The background-subtracted intensity value of each spot was then divided by the median 
array intensity of each microarray. 
In the 32 tumor samples, 6 samples showed fusion products that were located 
within 7 genes. Normalized expression data for these genes were collected for all 32 sam-
ples. Per gene the expression in the sample with integration in that gene was compared 
to samples with or without an identified fusion product. Graphs were made using Graph 
Pad Prism 5. 
HPV16 oncogene expression by RT-PCR
RNA isolated from 61 samples of which sufficient RNA was available after APOT analy-
sis, was reverse transcribed using the iScript cDNA Synthesis Kit (BioRad Laboratories, 
Hercules, CA, USA). RT-PCR reactions were performed using SensiMix SYBR & Fluo-
rescein (GC Biotech, Alphen a/d Rijn, the Netherlands). The following HPV-specific 
primers were used (see figure 1): E2 (87 bp product) forward primer 5’- TGATAG-
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TACAGACCTACGTGACCATATAGA-3’ (Primer Express v2.0 (Applied Biosystems, 
Carlsbad, USA)) and reverse primer 5’- ATTACAAGGCCAGAGAAATGGG-3’ (Prim-
er Express); E6 (106 bp product) forward primer 5’-CAGTTATGCACAGAGCTG-
CAA-3’32 and reverse primer 5’- ATGACTTTGCTTTCGGGATT-3’32; E7 (86 bp prod-
uct) forward primer 5’-AGAGGAGGAGGATGAAATAGATGGT-3’and reverse primer 
5’-CAATATTGTAACCTTTTGTTGCAAGTG-3’ (designed using Primer-BLAST (Na-
tional Center for Biotechnology Information (NCBI))33. Because of limited material, E7 
expression analysis was performed on 45 samples. The detection of the housekeeping 
gene Hypoxanthine Phosphoribosyltransferase (HPRT) was used for normalization of 
mRNA levels: forward primer 5’CACTGGCAAAACAATGCAGACT -3’ and reverse 
primer 5’GTCTGGCTTATATCCAACACTTCGT -3. Cell lines SiHa and CaSki were 
used as positive controls, and the HPV18-positive cell line HeLa was used as a control 
for HPV16 specificity. 
Fluorescence In Situ Hybridisation (FISH) for HPV16
FISH was performed as described previously, on 4 μm thick paraffin embedded tissue sec-
tions of 61/75 samples for which formalin-fixed, paraffin-embedded tumor blocks were 
available5,25,34. Briefly, sections were deparaffinised, pretreated with 85% formic acid/0.3% 
H2O2, 1 M NaSCN and 4 mg/ml pepsin, postfixed in 4% formaldehyde in PBS and de-
hydrated in an ascending ethanol series. For the co-localization experiments, we used 
biotin-labelled HPV16 probes (PanPath, Amsterdam, the Netherlands) together with di-
goxigenin-labelled BAC-clones containing human DNA sequences also identified in the 
viral-human fusion PCR products obtained by APOT/DIPS PCR. These BAC clones were 
grown according to the manufacturer’s instructions (BACPAC Resources Centre, Child-
rens Hospital Oakland Research Institute, Oakland, USA). DNA was isolated using the 
Nucleobond BAC-100 kit (BioKé, Leiden, the Netherlands). Both probes were applied un-
der a coverslip in a hybridization mixture containing 2 ng/μl HPV16 probe, 10 ng/μl BAC 
probe, 50% formamide, 2 × SSC pH 7.0, 50x excess salmon sperm DNA (Sigma) and 10x 
excess human CoT DNA.
Figure 1. HPV16 genome showing the localization of the RT-PCR-products obtained for E2, E6 and E7 viral oncogenes.
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Probes and tissue DNA were denatured simultaneously for 5 minutes at 80°  C prior to 
hybridization overnight at 37° C in a humid chamber. After hybridization the preparations 
were washed stringently in 2 × SSC + 0.05% tween-20 at 42° C (2 times 5 min), 0.1 × SSC at 
61° C (2 times 5 min) and 4 × SSC + 0.05% tween-20 at RT. Biotin-labelled probe was de-
tected using peroxidase-conjugated-avidine (Dako, Glostrup, Denmark; 1:200 diluted in 4x 
SSC containing 5% non-fat dry milk; 30 minutes at 37° C) and biotin-conjugated goat-anti-
avidine (Vector laboratories, Burlingame, CA; 1:100 diluted in 4 × SSC containing 5% non-
fat dry milk; 30 minutes at 37° C). Thereafter, a tyramide signal amplification reaction was 
performed under a coverslip by applying 50 μl Cy3-labelled tyramide in PBS containing 
0.1 M imidazole, pH 7.6 and 0.001% H2O2 for 10 minutes at 37° C. The digoxigenin-labelled 
probe was detected using mouse-anti-digoxigenin (Dako; 1:200), followed by TRITC-con-
jugated rabbit-anti-mouse (Dako;1:1000) and finally TRITC-conjugated swine-anti-rabbit 
(Dako; 1:100); incubated for 30 minutes at 37° C. Finally, slides were washed and dehy-
drated in an ascending ethanol series and mounted in Vectashield (Vector laboratories, 
Burlingame, CA) containing 4',6-diamidino-2-phenylindole (DAPI; Sigma; 0.2 μg/μl).
Viral load
Viral load of HPV16 was determined using real-time fluorescence PCR with type-specific 
primers and probes as described earlier26. Briefly, viral load was expressed as the num-
ber of HPV16 DNA copies per β-globin-gene copy. Gene copy numbers of β-globin were 
determined using the LightCycler-Control Kit DNA (Roche Molecular Biochemicals) 
according to the manufacturer’s instructions as previously described37. Calculation of 
initial copy numbers in samples was performed by the LightCycler 480 software (Ver-
sion 1.5) using a standard curve generated with exactly quantified HPV DNA standards 
(ten-fold dilution series of full length HPV16 plasmid) that were amplified in the same 
PCR run35-37. The analytical sensitivity of the assay was ten copies of HPV16 standard DNA. 
A negative control (water or DNA extracted from RTS3B cells that are negative for HPV) 
was included in each run and never yielded fluorescence signals above the background36.
Statistics
Differences in viral and human gene expression levels were analyzed using a  2-tailed 
Fisher’s exact test after testing for equality of variances. A significance level of p ≤ 0.05 
was chosen for all analyses. To test whether a  single sample deviated from a group of 
samples, SPSS was used to identify outliers. This was defined as any value that lays more 
than 1.5 times the interquartile range below the first quartile in a Box-and-Whisker Plot 
from all samples, or more than 1.5 times the interquartile range above the third quartile. 
All calculations were performed using IBM SPSS Statistics 19. 
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Results
Detection of viral integration by DIPS- and APOT-PCR
Table 1 in chapter 3 and figure 1 in chapter 3 summarize the integration sites of HPV16 
into the genome of 29 of the 75 HPV16 DNA- and p16INK4A-positive OPSCC (39%) as 
identified by DIPS- and APOT-PCR. Exclusively episomal PCR products were detected 
in the remaining 46 tumors (61%). 
In the 29 tumors with viral integration a total of 37 fusion products were identi-
fied, of which 10 harbored cellular sequences corresponding to intergenic regions and 
27 to known or predicted genes, including 12 tumor-related genes (BCL2, BRE, EPHA7, 
FANCC (2x), HDAC2, INO80C, LEPREL1, SYNPO2, TP63, TRAF3, TUBD1), 5 genes 
involved in deregulated tumor-related pathways (ERC2, GARS, SLC7A1, SYN3, ZMAT4), 
and 10 genes with no known role in tumorigenesis. All genes were verified using the 
ATLAS of genetics and cytogenetics in oncology and hematology Database38 and the Uni-
ProtKB Database39. 
Detection of gene expression
Subsequently, we analyzed whether HPV16 integration as detected by PCR, correlated 
with the level of expression of the invaded gene. In addition, we determined whether 
integration correlated with the expression of the viral genes E2, E6 and E7. 
Expression of genes disrupted by HPV
We extracted the level of expression of HPV-invaded genes from expression profiling 
data of a subset of 32 OPSCC, in which HPV16 integrated within a gene in 6 out of 32 
OPSCC, one of which contained two different integration sites (sample 10, table 1 in 
chapter 3). For each gene, its expression was compared between the single sample with 
HPV integration in the affected gene, the group of samples showing exclusively episomal 
PCR products (n=20) and the group of samples with fusion products harboring sequenc-
es derived from other chromosomal loci (n=11) (figure 2). In all cases there was no sig-
nificant change in the mean mRNA expression levels of the HPV-invaded genes between 
the subgroups with or without a fusion product. In the tumor with the HPV integration 
in the particular gene, the expression did not surpass the 1.5 interquartile range (IQR) of 
the group of samples with integration-derived fusion products, as calculated using SPSS, 
in 6 of the 7 genes. In the tumor with integration in the FANCC gene, the expression of 
the gene fell between 1.5 and 3 times the IQR and was considered a mild outlier. However, 
one additional sample without a fusion product surpassed the IQR more than 3 times and 
was considered an extreme outlier. 
93 
Chapter 4
In conclusion, our data suggest that the mRNA expression of a gene invaded by 
HPV16 does not differ from the expression of that gene in samples where it has not been 
disrupted by the virus. 
Viral gene expression
Viral gene expression could be assessed in 63 cases. APOT-PCR was able to detect a PCR 
product in 59 of these cases, however, the expression levels of E2, E6 and E7 as detected 
using qRT-PCR, varied widely. The viral gene expression of the 4 cases without detectable 
APOT-PCR product was nearly zero, indicating that the viral genome is not transcribed. 
When comparing cases in which a fusion transcript was detected using APOT-
PCR (i.e. actively transcribed fusion product) with the remaining cases, no significant dif-
ferences were seen in the mean log2 expression levels of either E2 (1717 vs. 97; p = 0.308), 
E6 (1859 vs. 195, p = 0.344) or E7 (1724 vs. 8, p = 0.2943) (see figure 3). Rather, a large 
variation in expression levels of these viral E2, E6 and E7 genes was observed, indepen-
dent of HPV integration status. 
Viral load
To determine whether viral load correlated with the integration status as determined using 
APOT- and/or DIPS-PCR and FISH, we have performed RT-DNA-PCR in 73 OPSCC samples. 
Viral load ranged from 6.8*10-6 up to 194 HPV DNA copies per β-globin gene 
copy. When comparing the average viral load in cases in which a fusion product was de-
Figure 2. Expression intensities for genes affected by HPV integration. The expression of a gene, affected by HPV integra-
tion in one sample, is compared to the expression of that gene in samples where exclusively episomal PCR products could 
be detected using APOT- and/or DIPS-PCR, and to the expression in samples where fusion products could be identified. 
Bars: Mean with standard deviation.
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tected using APOT- and/or DIPS-PCR with the remaining cases, no significant differenc-
es were seen (14 vs. 17 HPV DNA copies / β -globin; p = 0.683). No correlation was seen 
between the mean log2 expression levels of the viral genes E2, E6 or E7 and the viral load. 
Discussion
In this study we have comprehensively analyzed a large collection of 75 HPV16 positive 
OPSCC for their HPV16 physical status (episomal vs. integrated) and its relation to viral 
oncogene expression and virally disrupted human genes. In particular we were interested 
to see if cases with proven integration would show higher E6/E7 viral oncogene expres-
sion than E2 expression as suggested by studies with cervical cancer cell lines17,19-21. By 
detecting viral-human fusion products with APOT- and/or DIPS-PCR in 39% of these 
cases we provided direct evidence for viral integration. The so-called episomal products 
obtained by DIPS- and/or APOT-PCR in the remaining cases are indicative for the pres-
ence of episomal HPV DNA, although they by themselves provide no proof for this as-
sumption, because they could eventually also arise from integrated head to tail repeats 
of the viral genome. In this respect, two recently publisched studies have shown that 
Figure 3. Expression of the viral genes E2, E6 and E7 and viral load. (A-C) Expression of the viral genes has been normal-
ized to HPRT expression. (D) Viral load has been normalized to β-globin. E = episomal, E+I = episomal and integrated, 
I = integrated. Bars: Median with interquartile range.
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using -DIPS-PCR with other primer combinations or multiplex PCR followed by massive 
parallel sequencing may detect additional sites of HPV integration which is in agree-
ment with our findings comparing DIPS- and APOT-PCR40,41. The expression of HPV16 
interrupted genes as well as viral genes E2, E6 and E7 in these tumors, however, did not 
differ significantly from cases where no fusion product was detected. Furthermore, the 
cases with integration showed no notable differences in viral load in comparison with 
the remaining tumors. These data indicate that HPV16 integration in these tumors does 
not necessarily affect the levels of HPV-disrupted human gene transcripts and/or viral 
gene transcripts. Thus constitutive rather than a  high level of expression of oncogene 
transcripts appears to be required in HPV-related OPSCC.
We identified integration sites by APOT- and/or DIPS-PCR in 27 out of 75 OP-
SCC, of which 21 showed one, 5 showed two and 1 case showed four integration sites. 
In addition, 8 of these 27 tumors also harbored episomal viral DNA. Exclusively viral 
HPV16 DNA or RNA sequences indicating the presence of episomal virus were identi-
fied in the remaining 48 OPSCC. This finding is in agreement with results on a series of 
HPV16 positive cervical squamous cell carcinomas in which 55% showed viral integra-
tion by APOT-PCR11. In the OPSCC, integration sites showed to be distributed all over 
the human genome with half of them near fragile sites and some of them in previously 
detected clusters of viral integration (3q28, 8q24.21, 13q22.1 and 17q21)42. Interestingly, 
in 27 out of 37 detected sequences HPV16 directly interrupted known or predicted genes. 
Taken together, these data suggest that HPV16 integration is not simply a random event, 
but rather has a preference for less protected and more accessible chromosomal regions 
like transcribed tumor-genes and fragile sites. It can be speculated that integration takes 
place in genes which are highly expressed during carcinogenesis rather than that the in-
tegration itself affecting the genomic sites is the driving force.
We had access to mRNA expression profiling data of a subset of the OPSCC used 
in this study including 6 cases with proven integration (7 sites in total). In these cases in-
tegration of HPV16 occurred within gene sequences, including the known tumor related 
genes FANCC, HDAC2, SYNPO2 and TRAF3. Indeed, expression of FANCC and HDAC2 
genes has been reported to play a role in HNSCC43-46. Viral integration, however, did not 
lead to significantly different expression of the interrupted gene in comparison to OPSCC 
having integration in another DNA sequence or showing solely episomal virus. This is in 
contrast to a recent study of our group showing that integration of low-risk HPV6 in the 
AKR1C3 gene resulted in loss of gene expression in a laryngeal carcinoma47. In this case, 
however, the other gene copy was lost in the tumor as shown by array CGH analyses. In 
the 6 OPSCC studied here, no loss of the chromosomal regions containing the virally in-
terrupted genes has been detected by array CGH (Olthof, Lam, unpublished results). This 
indicates that one or more expressed gene copies are still present in these tumors, which 
can mask a possible effect of the integration on gene expression. On the other hand, this 
might also point to the fact that viral integration is not per se meant to deregulate the 
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interrupted gene in the cell, as also can be concluded by the finding of HPV16 integrated 
in intergenic sequences of 10 OPSCC in this study. In conclusion, these data suggest that 
if there is an effect of viral integration on carcinogenesis, affecting the genomic site is 
unlikely to be the driving force in OPSCC. Nevertheless, this has to be confirmed on the 
protein level in further studies.
Alternatively, integration might have an effect on viral oncogene E6 and/or E7 
expression. In this respect it has been hypothesized that integration leads to disruption 
of the viral E2 gene, which as a consequence cannot regulate E6 and E7 gene expression 
anymore from the LCR promoter region. Our DIPS-PCR data show that integration al-
ways affected the E2 gene, either by disrupting the viral E2 gene itself (38%) or by disrupt-
ing the upstream E1 gene (62%), also leading to E2 loss. Nevertheless, in most of these 
tumors E2 mRNA transcripts were detectable at different levels of expression and these 
transcript levels did not differ significantly from those detected in OPSCC with episomal 
virus. This is in contrast to the results of Häfner et al., which showed a decrease in E5 
transcript levels (downstream of E2) in uterine cervical lesions with integrated HPV1622. 
Nevertheless, a  rather constant transcription level of E6 oncogene transcripts was de-
tected independent of the physical status of the virus in these lesions. In OPSCC, we also 
observed a broad distribution for E6 and E7 transcript levels independent of a detected 
viral integration event. This points to the fact that a constitutive expression of viral tran-
scripts seems to be required within tumors. Only in a few cases very high levels of viral 
gene transcripts (E2  as well as E6 and E7) were detected, indicating that mechanisms 
other than E2 binding to the viral LCR promoter region might influence transcription 
levels such as methylation of the LCR region48,49.
In conclusion our data indicate that HPV physical status (extrachromosomal epi-
somes or host DNA integrated) does not affect the levels of viral and/or HPV-disrupted 
human gene transcripts. Therefore constitutive and not a high level of expression of on-
cogene transcripts appears to be required in HPV-related OPSCC. 
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Abstract
Introduction. Although patients with HPV-related HNSCC generally have a better prog-
nosis when compared to patients with non-HPV-associated HNSCC, a subgroup of 
HPV-positive patients with poor prognosis has been recognized, particularly related to 
smoking, EGFR overexpression and chromosomal instability. In addition, viral integra-
tion into the host genome might contribute to carcinogenesis, as is shown for cervical 
carcinomas. For HNSCC, the reported integration frequencies vary widely, and have so 
far not been correlated to prognosis or response to therapy. Therefore, all seven reported 
HPV16-positive HNSCC cell lines have been carefully analysed for viral and host ge-
nome parameters. 
Methods. The viral integration status, viral load, viral gene expression and the presence 
of aneusomies was evaluated in the cell lines: UD-SCC-2, UM-SCC-047, UM-SCC-104, 
UPCI:SCC090, UPCI:SCC152, UPCI:SCC154 and 93VU147T. HPV integration was ex-
amined using FISH, APOT- and DIPS-PCR. Viral load and the expression of the viral 
genes E2, E6 and E7 was determined via quantitative PCR. 
Results. All cell lines showed integration-specific staining patterns using FISH. APOT- 
and DIPS-PCR revealed integration-derived fusion productsin six cell lines, and only 
episomal PCR products for UM-SCC-104. Viral load ranged from 1 up to 739 copies per 
cell and all but one (UPCI:SCC154) cell lines showed aneusomy.  
Conclusions. All HPV16-positive HNSCC cell lines available have been meticulously 
analysed for HPV-related parameters. These cell lines were shown to contain both epi-
somal and integrated DNA as well as parameters associated with a poor prognosis, mak-
ing them very suitable model systems for the development of new antiviral therapies, 
specifically directed towards this subtype of HPV-related HNSCC. 
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Introduction
Infection with high-risk human papillomavirus (HPV) is a causative factor for the de-
velopment of several types of neoplasms, including cervical, anogenital and a subset of 
head and neck cancers. Although most head and neck squamous cell carcinomas (HN-
SCC) can be attributed to the exposure to environmental factors, such as excessive to-
bacco- and alcohol use, approximately 20–25% of these cancers are caused by infection 
with HPV16. Notably, HPV-induced tumors are preferentially found in the oropharynx, 
where up to 90% of the malignancies are associated with HPV1-5. 
Patients with HPV-induced carcinomas display clinical and molecular character-
istics that are distinct from those in patients with tobacco- and alcohol-induced tumors. 
It is now well accepted that patients with HPV-derived tumors have a favourable progno-
sis, independent of the chosen treatment strategy6-12. 
As a result, as first described by Ang et al.6, HNSCC can be divided into three 
risk groups, depending on HPV status, the number of pack-years of tobacco smoking 
and nodal stage: 1) Patients with HPV-positive HNSCC that had < 10 pack-years, or pa-
tients with HPV-positive HNSCC that had >10 pack-years and had N0-N2a carcinomas 
were considered to be at low risk for disease-related death; 2) Patients with HPV-positive 
tumors, > 10 pack-years and a nodal status of N2b-N3 or patients with HPV-negative 
T2-T3 tumors that had < 10 pack-years were considered to be at intermediate risk; 3) 
Patients with HPV-negative tumors and > 10 pack-years, or patients with HPV-negative 
T4 tumors and < 10 pack years were considered to be high risk. In addition, it was shown 
that EGFR overexpression negatively affects overall survival both in HPV-positive as well 
as in HPV-negative tumors. Chromosomal instability was also reported to have a nega-
tive influence on prognosis, especially in HPV-positive tumors13. These data indicate that 
smoking, advanced nodal stage, EGFR overexpression and chromosomal instability are 
risk parameters for poor prognosis in HPV-associated HNSCC6,13. 
From uterine cervical (pre)malignancy models it is hypothesized that integration 
of HPV into the host genome plays an important role in the carcinogenic process. It cor-
relates with the severity and progression of these lesions14,15 and is considered a risk factor 
for the development of uterine cervical squamous cell carcinoma15. In addition, a higher 
viral load is associated with higher grade lesions. It is, however, not possible to predict 
tumor progression based on the integration status of HPV or the viral load16. 
HNSCC, in particular oropharyngeal squamous cell carcinomas, are mostly dis-
covered as metastatic disease and data on premalignant lesions are scarce. Therefore lim-
ited information is available on the role of viral integration in the development of these 
tumors. It is hypothesized, however, that viral integration also promotes carcinogenesis 
in HNSCC, but this is not substantiated by clinical studies on premalignant lesions, as is 
the case for cervical lesions. 
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Furthermore, the reported integration percentages in HNSCC vary considerably, 
ranging from 0% to almost 100% in different publications17-20. This extreme variation 
might be explained by the different patient populations studied, the different methods 
applied to study viral integration and a lack of correlation between these methods. 
However, the integration status of the virus can be of significance in relation to 
treatment. Chang et al.21 and Herdman et al.22 have shown a clear difference in the re-
sponse of keratinocytes with episomal versus integrated HPV. Using these cell line mod-
els it could be shown that interferon therapy can eradicate episomal HPV infection, but 
leads to a growth advantage for cells containing integrated HPV. This indicates that an-
tiviral therapies might be influenced by the viral integration status. Thus, it is imperative 
to have a well-characterized model for HPV-associated HNSCC, for which the physical 
status of the virus is known. 
This study presents a detailed analysis of the integration status in 7 HPV-positive 
HNSCC cell lines is presented, which have been established from HPV-induced tumors. 
The integration status has been assessed using a set of independent techniques, i.e. FISH, 
APOT- and DIPS-PCR. In addition, the expression levels of the viral genes E2, E6 and E7 
and the expression levels of EGFR, as well as the viral load were analyzed. 
Materials and methods
Cell lines
Human HPV16-positive HNSCC cell lines were obtained from different sources. Cell lines 
UPCI:SCC090, UPCI:SCC152 and UPCI:SCC154 were kindly provided by Dr.Susanne 
Gollin from the University of Pittsburgh, Pittsburgh, USA. The UPCI:SCC152 cell line 
was established from a recurrence in the patient from which the cell line UPCI:SCC090 
was derived23. Cell line UD-SCC-2 was a kind gift from Dr. Thomas Hoffmann; pres-
ent address University of Ulm, Ulm, Germany24. The cell lines UM-SCC-047 and UM-
SCC-104 were a kind gift from Dr. Thomas Carey, University of Michigan, Michigan, 
USA25,26. The cell line 93VU147T was provided by Dr. J.P. de Winter, Free University 
Medical Centre, Amsterdam, the Netherlands27. Clinicopathological data of the patients 
and tumors from which the cell lines were derived are given in table 1. 
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Table 1. Characteristics of patients from which the cell lines have been derived. 
Cell line UD-SCC-2 UM-SCC-47 UM-SCC-104
UPCI: 
SCC090
UPCI: 
SCC152
UPCI: 
SCC154 93VU147T
M/F M M M M M M M
Age at 
diagnosis 58 53 56 46 47 54 58
Smoking y y y y y y y
Alcohol y n.a. y y y y y
Primary tumor 
site
hypo-
pharynx
lateral 
tongue
floor of 
mouth
base of 
tongue
hypo-
pharynx tongue
floor of 
mouth
TNM T1N3 T3N1M0 T4N2bM0 T2N0 recurrence T4N2 T4N2
Differentiation n.a. M/W P/M P M n.a. M
Abbreviations: M: Male; F: Female; n.a.: not available; W: well differentiated; M: medium differentiated; P: 
poorly differentiated.
Cell lines UD-SCC-2 and 93VU147T were cultured in MEM (Invitrogen, Carls-
bad, CA, USA) containing 10% FCS (Sigma, St Louis, MO, USA), 2 mM glutamine (In-
vitrogen), 0.1 mM MEM non-essential amino acids (Invitrogen) and 0.005% gentamycin 
(Eurovet Animal Health BV, Bladel, the Netherlands). The remaining cell lines were cul-
tured in DMEM (Invitrogen) containing the same additives as described above. Cell lines 
UM-SCC-047, UPCI:SCC090 and UD-SCC-2 were received in 2008 and UM-SCC-104, 
UPCI:SCC152, UPCI:SCC154 and 93VU147T in 2011 and were frozen immediately 
upon arrival. All cell lines were confirmed to have unique genotypes, as tested using the 
ProfilerPlus assay, except the cell lines UPCI:SCC090 and UPCI:SCC152, which shared 
the same genotype as they are derived from the same patient (see supplementary table 1). 
Cell lines in culture were regularly tested for infection with mycoplasma. 
The uterine cervical cancer cell lines SiHa and CaSki were used as HPV16- and 
p16INK4Apositive controls in p16INK4A immunostainings and HPV16-specific PCR analy-
sis. The uterine cervical cancer cell line HeLa, the HPV-negative HNSCC cell lines 
UPCI:SCC003, and the osteosarcoma cell line U2OS containing the empty pJ4Ω-vector28 
were used as negative controls in these assays. The latter cell line harbouring HPV16-E2-
containing pJ4Ω-vector was used as a positive control for HPV16-E2 RT-PCR.
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DNA/RNA extraction
DNA was isolated from cultured cells using QIAamp DNA Blood Mini Kit (Qiagen, 
Hilden, Germany) as per the manufacturers’ instruction. Total RNA was extracted using 
the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions, including 
DNase treatment. RNA concentration and quality were determined by RNA standard 
sense chips on a BioRad Experion system (BioRad, Munich, Germany).
HPV DNA PCR
The presence of HPV DNA was detected by PCR using the consensus primer set 
GP5+/6+29, followed by type-specific primers for HPV16 and HPV18. The following 
primers were used: 
Target Primer Sequence
HPV16 Forward 5’- ACAGGAGCGACCCAGAAAGTTAC-3’
Reverse 5’ GCATAAATCCCGAAAAGCAAAGT-3’
HPV18 Forward 5’CACATTGGAAAAACTAACTAACACACTGG-3’
Reverse 5’CAGCTATGTTGTGAAATCGTCGTT-3’
Primers were synthesized by Biolegio BV, Nijmegen, the Netherlands. 
Five μl of PCR product were separated on a 1.5 % agarose gel and visualized Gel-
Star Nucleic Acid Gel Stain (Cambrex Bio Science Rockland Inc., Rockland, USA). 
Viral load
Viral load of HPV16 was determined using real-time fluorescence PCR with type-specific 
primers and probes as described earlier30. Briefly, viral load was expressed as the number 
of HPV16 DNA copies per β-globin-gene copy. Gene copy numbers of β-globin were deter-
mined using the LightCycler-Control Kit DNA (Roche Molecular Biochemicals) accord-
ing to the manufacturer’s instructions as previously described31. Calculation of initial copy 
numbers in samples was performed by the LightCycler 480 software (Version 1.5) using 
a standard curve generated with exactly quantified HPV DNA standards (ten-fold dilution 
series of full length HPV16 plasmid) that were amplified in the same PCR run30-32. The 
analytical sensitivity of the assay was ten copies of HPV16 standard DNA. A negative con-
trol (water or DNA extracted from RTS3B cells that are negative for HPV) was included in 
each run and never yielded fluorescence signals above the background31.
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Viral integration analysis
The detection of viral integration can be studied by various methods. Most common-
ly used are methods based on the DNA-ratio of the oncoproteins E2 and E6, based on 
reports in uterine cervical carcinomas showing that integration of HPV often leads to 
disruption of parts of the E2 gene region, while retaining intact E6 and E7 oncogenes33. 
However, for HNSCC it has been shown that HPV is able integrate in tandem head- to-
tail arrays of complete but linearized HPV DNA genomes34, which implies that methods 
based on the E2/E6 DNA-ratio might underestimate the percentage of integration.
In situ hybridisation (ISH), either fluorescent (F) or chromogenic (C), can be used 
to visually determine the integration status of the virus. This method differentiates be-
tween episomal and integrated virus based on the signal pattern in the nucleus of the 
infected host cell, whereby a punctate pattern indicates integration and a diffuse signal 
indicates episomal virus35. Sensitive (F)ISH assays have been described that are able to 
detect a single copy of HPV per cell36. However, this also implies that a single or few epi-
somal copies of HPV could display a punctate pattern, and subsequently be interpreted as 
integration, thus resulting in overestimation of the viral integration frequency. 
The physical status of HPV can also be assessed by identifying viral-human fu-
sion products. The two most commonly used methods are Detection of Integrated Papil-
lomavirus Sequences (DIPS-PCR), which amplifies the genomic fusion region between 
viral and cellular DNA downstream the integration locus, and 3‘-RACE-PCR (Amplifica-
tion of Papillomavirus Oncogene Transcripts; APOT-PCR), which detects integration-
derived mRNA transcripts. Subsequent sequencing of the obtained PCR products can be 
used to identify the integration locus. 
While methods based on E2/E6 DNA- ratios can only detect integration status 
(integrated versus episomal), APOT- and DIPS-PCR as well as (F)ISH can also provide 
information on the number of integration events. 
However, determining viral integration frequency is hindered due to disconcor-
dance between different methods. Therefore, the effect of viral integration on response to 
therapy and therefore prognosis is hard to estimate. 
Fluorescence in situ Hybridisation
HPV16-specific probes were purchased from PanPath, Amsterdam, the Netherlands. BAC-
clones, used for colocalization experiments, were grown according to the manufacturer’s 
instructions (BACPAC Resources Centre, Childrens Hospital Oakland Research Institute, 
Oakland, USA). DNA was isolated using the the Nucleobond BAC-100 kit (BioKé, Leiden, 
the Netherlands). Probes for centromeres (CEPs) 1, 3 and 9 were available in our lab, previ-
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ously described in Hopman et al.37. Probes and clones were labelled using either the Dig-
nick translation kit or the Biotin-nick translation kit (Roche, Basel, Switzerland), according 
to the manufacturer’s instructions. Labelled CEP probes for CEP17 and CEPX were kindly 
provided by the Department of Clinical Genetics, Maastricht University Medical Centre, 
Maastricht, the Netherlands. To exclude possible hybridization to RNA transcripts cells were 
treated with 10 ng/ml ribonuclease A (Qiagen) in a control experiment. 
Fluorescence in situ hybridisation (FISH) was performed as described earlier3,38,39. 
Briefly, cells were fixed in 70% ethanol, spotted on glass slides, airdried for 15 minutes and sub-
sequently baked for 30 minutes at 80° C. After cooling, slides were incubated with 0.01% pepsin 
(800-1200 U/mg protein from porcine stomach mucosa; Sigma) in 0.01N HCl for 20 minutes at 
37° C, washed and postfixed in 1% formaldehyde in PBS for 10 minutes at RT. Slides were then 
dehydrated in an ascending ethanol series and airdried. Probes were applied under a coverslip 
according to the manufacturer’s instructions. Probe and target DNA were denatured simulta-
neously for 3 minutes at 80° C prior to hybridization overnight at 37° C in a humid chamber. 
After hybridization the preparations were washed stringently in 2 × SSC/0.05% tween-20 at 
42° C, 0.1 × SSC at 61° C and 4× SSC/0.05% tween-20 at RT for 2 × 5 minutes each. Biotin-
labelled probe was detected using FITC-conjugated-avidine (Dako, Glostrup, Denmark; 1:500) 
followed by biotin-conjugated goat-anti-avidine (Vector laboratories, Burlingame, CA; 1:100) 
and finally FITC-conjugated-avidine (Dako; 1:500); incubated for 30 minutes at 37° C. In cases 
where two hybridisation probes were used simultaneously, biotin-labelled probes was detected 
as described above. The digoxigenin-labelled probe was detected using mouse-anti-digoxigen-
in (Dako; 1:200), followed by TRITC-conjugated rabbit-anti-mouse (Dako; 1:1000) and finally 
TRITC-conjugated swine-anti-rabbit (Dako; 1:100); incubated for 30 minutes at 37° C. Finally, 
slides were washed and dehydrated in an ascending ethanol series and mounted in Vectashield 
(Vector laboratories) containing 4’,6-diamidino-2-phenylindole (DAPI; Sigma; 0.2 μg/μl). 
Images were acquired using a Leica DMRXA microscope (Leica, Wetzlar, Germa-
ny) equipped with optical filters for DAPI, fluorescein and TRITC and a 63× Plan Apo 
(NA 1.32) objective. The microscope was connected to a digital black and white CCD cam-
era (Metasystems Image Pro System, Sandhausen, Germany) for image recording. Stain-
ing patterns were scored according to the criteria first described by Cooper et al.35, where 
a punctate signal indicates integrated virus, and a diffuse pattern indicates extrachromosal 
viral copies.
Metaphase spreads 
Metaphase spreads were made as described in40, with minor adjustments. Briefly, cells were 
cultured until approximately 50% confluency. Medium was then replaced by medium con-
taining 0.1-0.5 μg/ml colcemid (Sigma) and 0-0.01 μg/ml ethidium bromide and incubated 
for 2-4 hours at 37° C. Optimal conditions varied per cell line. After incubation, cells were 
trypsynized and subsequently treated with 0.075 M KCl for 10 minutes at 37°  C. Cells 
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were washed twice and fixed in methanol/acetic acid (3:1, v/v). FISH probes were used 
for hybridisation as outlined above, with minor adjustments. Slides were only incubated 
for 8 minutes with 0.01% pepsin (800-1200 U/mg protein from porcine stomach mucosa; 
Sigma) in 0.01N HCl at 37° C. After washing, slides were dehydrated in an ascending etha-
nol series, and airdried. Slides were then baked for 10 minutes at 56° C. Postfixation was 
performed in 4% formaldehyde in PBS for 10 minutes at RT. After postfixation, the proto-
col was followed as described above. 
Amplification of Papillomavirus Oncogene Transcripts (APOT-PCR)
HPV oncogene transcripts were amplified as described before15 (and chapter 4). Briefly, 
reverse transcription was performed using 25 μM oligo-(dT)17 primer coupled to a linker 
sequence (dT)17-p3, 10 mM dNTPs each, 0.1 M DTT, 5x RT-buffer and SuperScript re-
verse transcriptase (Invitrogen, Karlsruhe, Germany)41. Quality of cDNA was determined 
by a standard GAPDH gene PCR. First-strand cDNAs containing viral oncogene sequenc-
es were subsequently amplified with semi-nested PCR using HPV-E7 specific 5’primers 
and oligo(dT) and adaptor primers (3’). PCR products were separated on a 1.2% agarose 
gel. Bands typical for integration were cut out, purified (QIAGEN Gel extraction kit, QIA-
GEN, Hilden, Germany) and sequenced (GATC Biotech, Konstanz, Germany). Sequence 
results were analyzed using the BLASTN program42 and further mapped using map view-
er, both provided by the National Center for Biotechnology Information (NCBI)43. 
Detection of Integrated Papillomavirus Sequences (DIPS-PCR)
Integrated papillomavirus sequences were detected using the Detection of Integrated 
Papillomavirus Sequences-PCR (DIPS-PCR) assay, as described earlier44 (and chapter 4). 
Shortly, genomic DNA was digested using the Sau3AI restriction enzyme and an enzyme-
specific adapter was ligated to the restriction-digested DNA using T4 DNA ligase (Roche 
Diagnostics, Mannheim, Germany). Linear PCR was performed using 5 HPV16 specific 
forward primers in independent setups. All independent PCRs were followed by individual 
exponential PCRs using further virus-specific forward primers and the AP1 reverse primer. 
PCR products were separated on a 1.2% agarose gel and products of interest were excised 
and subsequently sequenced (GATC Biotech). Sequence results were analyzed using the 
BLASTN program42 and further mapped using map viewer, both provided by the NCBI43. 
mRNA expression of HPV16 E2, E6 and E7 and human EGFR
RNA was reverse transcribed using the iScript cDNA Synthesis Kit (BioRad Laboratories, 
Hercules, CA, USA). Real-time PCR reactions were performed using SensiMix SYBR & 
Fluorescein (GC Biotech, Alphen a/d Rijn, the Netherlands). The detection of the house-
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keeping gene hypoxanthine phosphoribosyltransferase (HPRT) was used for normalization 
of mRNA levels. Primer sequences for HPRT were kindly provided by prof. dr. L. Hofland 
from Erasmus Medical Centre, Rotterdam, the Netherlands. The following primers, syn-
thesized by Biolegio BV, were used:
Target Primer Sequence Ref
HPV16 E2 Forward 5 TGATAGTACAGACCTACGTGACCATATAGA-3’
Reverse 5’- ATTACAAGGCCAGAGAAATGGG-3’
HPV16 E6 Forward 5’-CAGTTATGCACAGAGCTGCAA-3’ 45
Reverse 5’- ATGACTTTGCTTTTCGGGATT-3’
HPV16 E7 Forward 5’-AGAGGAGGAGGATGAAATAGATGGT-3’   46
Reverse 5’-CAATATTGTAACCTTTTGTTGCAAGTG-3’   
EGFR Forward 5’-CCAAGGGAGTTTGTGGAGAA-3’
Reverse 5’ CTTCCAGACCAGGGTGTTGT 3’
HPRT Forward 5’ CACTGGCAAAACAATGCAGACT -3’ 47
Reverse 5’ GTCTGGCTTATATCCAACACTTCGT -3’
Results
Active HPV16 infection is present in all cell lines
All cell lines have been tested for active HPV16 infection, using the algorithm suggested 
previously48. The cell lines showed overexpression of CDK-inhibitor p16INK4A using im-
munocytochemistry on AgarCyto blocks, which is routinely used as a surrogate marker 
for HPV infection (see figure 1A). Furthermore, the presence of HPV16 DNA has been 
shown by PCR, first using the consensus primers GP5+/6+ and subsequently by using 
type-specific primers for HPV16- and -18 (see figure 1B). RT-PCR analysis of the viral 
oncogenes E6 and E7 showed viral gene expression in all cell lines (see below). 
Viral load
HPV16 load in all cell lines was estimated using PCR, and was expressed as the number 
of HPV16 copies per β-globin copy. Viral load varied from 1 (UM-SCC-104) up to 739 
(UPCI:SCC090) HPV16 copies per β-globin gene copy (see table 2). 
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FISH integration analysis
All cell lines were tested for the presence of HPV16 DNA using FISH and they all showed 
a reproducible punctate nuclear signal, which indicates viral integration. Each cell line 
showed a specific number of FISH signals per nucleus, ranging from 2 (UD-SCC-2 and 
UPCI:SCC154) to 7 (93VU147T) (figure 1C). UPCI:SCC090 and -152, derived from the 
same patient, showed identical spot numbers. UM-SCC-104, however, showed a  vari-
able number of signals per nucleus, ranging from 1 to 4 (table 2). Notably, cell lines with 
a high viral load exhibited a higher number and/or more intense FISH signals (see figure 
1C and table 2) and also showed stronger HPV16-specific PCR bands on agarose gel (see 
figure 1B). Possible hybridization to RNA transcripts was excluded by treating the cells 
with RNAse in a control experiment. 
Identification of HPV16 integration sites by PCR
APOT-PCR, a PCR-based method that can amplify both viral-human fusion transcripts 
as well as episome-derived viral transcript, was used to identify the site of viral integra-
tion in the cellular genome. A single integration site was identified in 5 cell lines (UM-
SCC-047, UPCI:SCC090, UPCI:SCC152, UPCI:SCC154 and 93VU147T)(see table 3). 
Sequencing analysis of the obtained viral-human fusion transcripts revealed viral inte-
gration in 3 genes and in 2 intergenic regions. The protein-coding regions identified were 
DIAPH2, exon 21 (UD-SCC-2), TP63 exon 7 (3q28, UM-SCC-047) and NAP1 exon 4 
(9q22.33, UPCISCC:090 and UPCI:SCC152; both derived from two subsequently diag-
nosed recurrent tumors from the same patient). The intergenic regions identified were 
located on chromosomes 17q12 (93VU147T) and 21q11.2 (UPCI:SCC154). 
All fusion transcripts detected by APOT-PCR showed type A  splicing as de-
scribed by Klaes et al.49 from viral nucleotide 880 directly into the human sequence in 
sense orientation with the identified gene (see also chapter 3). Interestingly, only episom-
al transcripts could be identified in the UM-SCC-104 cell line, suggesting the presence 
of complete episomes, either integrated or extrachromosomal.DIPS-PCR was performed 
to verify the identified integration sites and to search for possible viral-human fusion 
products in the cell line where no fusion transcript could be identified using APOT-PCR 
(UM-SCC-104). No fusion product could be amplified in this cell line, although the pres-
ence of episomal viral copies was confirmed. In the remaining cell lines the integration 
sequences identified using APOT-PCR were confirmed by DIPS-PCR. DIPS-PCR iden-
tified the integration site in the UPCI:SCC154 cell line to be located within the NRIP1 
gene. Identified integration sites are portrayed in figure 2 and summarized in table 3. 
To confirm that the identified human sequences were localized adjacent to the vi-
ral genome, double-target FISH analysis was performed using both the HPV16 probe and 
BAC-probes complementary to the putative integration sequence (see figure 3A). BAC-
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probes were shown to colocalize with all HPV16 signals in two cell lines (UM-SCC-047 
and UPCI:SCC154). In three additional cell lines, HPV16 signals were also detected with-
out colocalization with the BAC-probe (UPCI:SCC090, UPCI:SCC152 and 93VU147T). 
HPV mapping on metaphase preparations
For the cell lines in which the integration loci did not colocalize to a  BAC-probe 
(UM-SCC-104, UPCI:SCC090 and 93VU147T), HPV16 FISH analysis in combina-
tion with karyotyping based on inverted DAPI staining was performed on metaphase 
preparations. All data are summarized in table 2. In the UPCI:SCC090 cell line ad-
ditional integration events were mapped to chromosomes 3 and 6, which is in agree-
ment with data from Ragin et al.50. Interestingly, in the metaphase preparations of the 
UM-SCC-104 cell line, metaphase chromosomes did not show HPV16 FISH signals, 
whereas interphase cells, also present in the preparation, did show a nuclear FISH 
staining pattern similar to the staining on 70% ethanol suspensions (see figure 1C). 
This was shown in repeated experiments with different observers (JvL, E-JS, NO). Al-
Figure 1. 
A)  Representative examples of p16INK4A staining in cell lines UD-SCC-2 (HPV16 positive) and UPCI:SCC003 (HPV-negative)
B)  HPV16-specific PCR. Lane 1 shows the 100 bp, 200 bp and 300 bp fragments of a 100 bp ladder for fragment size 
determination, lane 2-12 show the results of the HPV16 specific PCR. Lane 2: UD-SCC-2; lane 3: UM-SCC-047; lane 
4: UPCI:SCC090; lane 5: UM-SCC-104; lane 6: UPCI:SCC152; lane 7: UPCI:SCC154; lane 8: U2OS cell line with the 
empty pJ4Ω-vector as negative control; lane 9: 93VU147T; lane 10: HeLa (HPV18 cervix carcinoma cell line); lane 11: 
CaSki (HPV16 positive cervix carcinoma cell line); lane 12: water.
C)  HPV16 FISH staining pattern in the seven cell lines. HPV16 was detected using a FITC-labelled probe (green) and cell 
nuclei are stained with DAPI (blue).
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though this might be a sensitivity issue, another explanation might be that the virus is 
extrachromosomal, which is supported by the detection of only episomal transcripts 
by APOT- and DIPS-PCR (see above). 
Integration events and ploidy status
To determine whether multiple colocalizing FISH-signals indicated duplication or trans-
location of the involved chromosome, double-target FISH was performed on metaphase 
preparations of the cell lines, using both a  CEP-probe as well as an HPV probe. This 
showed that integration can be followed by deletion of the sister chromosome and du-
plication (UD-SCC-2) or multiplication (UM-SCC-047) of the chromosome containing 
HPV integration, with all respective chromosomes showing signals for both the CEP-
probe as well as the HPV16 probe. Duplication of chromosomes with concurrent dupli-
cation of the sister chromosome was also seen (UPCI:SCC090, UPCI:SCC152), shown 
by the presence of chromosomes containing only a signal for the CEP-probe as well as 
chromosomes containing signals for both CEP- and HPV16 probes. Lastly, duplication 
could also be accompanied by translocation of a small portion of the involved chromo-
some to a different chromosome (UM-SCC-047). 
Figure 2. HPV integration sites for the individual cell lines as detected by APOT- or DIPS-PCR. For each cell line the cor-
responding chromosome is displayed, portraying the identified integration site. 
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The detected multiplication of chromosomes is in line with the ploidy status of 
the different cell lines, which in 6 of the 7 cell lines showed copy number variations for 
chromosomes 1 and 7, a hallmark for chromosomal instability and aneusomy13 (table 2). 
Figure 3.
A)  Colocalisation of FITC-labelled HPV16 probes (green) with TRITC-labelled BAC clones (red) on interphase nuclei 
of UD-SCC-2 (BAC clone RP11-212B22), UM-SCC-047 (BAC clone RP11-373I6), UPCI:SCC090 and UPCI:SCC152 
(BAC clone RP11-23B15 for both), UPCI:SCC154 (BAC clone RP11-10J13) and 93VU147T (BAC clones RP11-
1331M22 and RP11-365D23, respectively). 
B)  Colocalisation of HPV16 probes with probes for CEPX (green), CEP3 (green) or CEP9 (red) on metaphase spreads of 
UD-SCC-2, UM-SCC-047 and UPCI:SCC090, respectively.
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Gene expression of HPV16 E2, E6 and E7 and human EGFR
To determine whether integration affects the expression of the viral genes, the expres-
sion levels of the viral genes E2, E6 and E7 were determined using RT-PCR (see figure 
4). Expression of the viral gene E2, which is known to regulate gene transcription of the 
oncogenes E6 and E7, was present at variable levels in six of the seven cell lines. Expres-
sion of the viral oncogenes E6 and E7 could be detected in all cell lines at variable levels, 
but no correlation could be found with the levels of E2 expression. Furthermore, no cor-
relation was found between the number of FISH HPV16 signals, viral load and viral gene 
expression. 
In addition, the level of EGFR expression was examined for each of the seven 
cell lines. This showed a variable expression of 0.4 (UPCI:SCC090) up to 5.6-fold (UM-
SCC-104) expression to HPRT. As the median EGFR expression in 61 primary HPV-
associated HNSCC is 0.3 fold to HPRT (range 0.001-18.6-fold to HPRT, unpublished re-
sults), this indicates an increased expression of EGFR in all cell lines. 
Figure 4.
A)  Expression of viral genes E2, E6 and E7 for each of the seven cell lines. Expression levels are displayed as x-fold change 
as compared to the expression of the housekeeping gene HPRT.
B)  Expression of EGFR for each of the seven cell lines. Expression levels are displayed as x-fold change as compared to the 
expression of the housekeeping gene HPRT.
A
B
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Discussion
HR-HPV infection is a well-established risk factor contributing to the development of 
HNSCC, particularly OPSCC. In recent years it has been shown that HPV-positive tu-
mors have different clinical and patho-biological characteristics, including a better prog-
nosis as compared to HPV-negative tumors48. It is still under debate which factors, in 
addition to the presence of HPV DNA and the resulting viral gene expression in the host 
cell, are contributing to tumor development and progression. For example, integration of 
the viral DNA into the host genome, and the resulting disruption of invaded genes might 
play an important role in the process of HPV carcinogenesis, as seen in HPV-associated 
cervical cancer51,52. In the case of HNSCC, not many studies have addressed this highly 
relevant issue 53-55 (and chapter 4). 
Since in vitro testing is still an important step in the development of new thera-
peutic options, it is imperative to be able to study well-established cell line models for 
HPV-positive HNSCC. In the underlying study, HPV16-associated parameters, such as 
viral load and integration, have been assessed in seven established HNSCC cell lines, 
shown to be HPV-induced by p16INK4A immunostaining and HPV-type-specific PCR. 
Integration of HPV DNA was detected in 6 of the 7 cell lines using three indepen-
dent methods, i.e. APOT- and DIPS-PCR and FISH, which all gave concurrent results with 
respect to the integration locus. Furthermore, for one of the cell lines (UPCI:SCC090) 
our results confirmed a previously reported integration site on 9q3150. Two cell lines that 
were derived from the same patient (UPCI:SCC090 and UPCI:SCC152), showed identi-
cal integration sites despite the fact that they were established from biopsies taken from 
different locations and at different time points, indicating clonal expansion of the tumor. 
One cell line (UM-SCC-104) did not show integration, but rather the presence of extra-
chromosomal HPV DNA, as assessed by APOT- and DIPS-PCR. 
We detected viral loads varying from 1 up to 739 HPV16 copies per β-globin gene 
copy. In contrast to results obtained from cervical malignancies56, viral load did not seem 
to be correlated to integration status. This can be concluded from the two cell lines show-
ing a viral load of 1 HPV DNA copy per β-globin copy, one of which showed HPV DNA 
integration and the other showed only episomal HPV. 
Cell lines with a higher viral load did exhibit strong punctate FISH signals, in-
dicating that the HPV genome may be present in integrated tandem repeats. This as-
sumption is supported by the finding that these strong signals are not derived from RNA 
transcripts, present at these loci, as shown by RNAse treatment before the FISH analysis 
(data not shown). Moreover, the cell lines showed 2 up to 7 HPV integration sites as 
detected with the FISH procedure, whereas in primary tumors generally only 1 signal 
per nucleus is detected13. To determine whether this is due to either multiplication of the 
integration locus, or a result of multiple independent integration events, co-hybridiza-
tion of HPV16 probes with a BAC-probe complementary to the identified integration 
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sequences was performed. In the cell lines UD-SCC-2, UM-SCC-047 and UPCI:SCC154 
all HPV16 signals were shown to colocalize with the BAC-probe, while in UPCI:SCC090, 
UPCI:SCC152 and 93VU147T the BAC-probe colocalized with part of the HPV16 FISH 
signals. The presence of more than one colocalizing signal indicates multiplication of the 
integration locus. Multiplication of an existing integration site was furthermore shown 
by co-hybridization of the HPV-probe with CEP-probes for the corresponding chromo-
some. For the UD-SCC-2 cell line, derived from a male patient, the two HPV16 FISH 
signals were located on two different CEPX-containing chromosomes, indicating that 
a duplication event has occurred. In the UPCI:SCC090 four chromosome copies contain-
ing CEP9 were detected, of which two harboured HPV16 signals, indicating duplication 
of both copies of chromosome 9. In the UM-SCC-047 cell line five HPV16 signals were 
detected on five separate chromosomes, of which four also containing CEP3, indicating 
multiplication of the initial integration site. The fifth chromosome contained very strong 
HPV- and BAC-signals but no CEP3 signal (see figure 3B), which might indicate that this 
chromosome evolved by a different mechanism, for example involving both transloca-
tion of part of chromosome 3 and amplification of the integration site. Figure 5 provides 
a schematic representation of the multiplication and translocation events identified in the 
HNSCC cell lines indicated. 
Besides HPV16 signals colocalizing with the BAC-probe in UPCI:SCC090, 
UPCI:SCC152 and 93VU147T cell lines, additional HPV16 signals were detected. The 
non-colocalizing HPV signals might indicate multiple independent integration events, 
which were not detected by APOT- or DIPS-PCR. A possible explanation for the fact 
that the APOT-PCR assay is unable to detect all the different integration sequences may 
be that (several of) these sequences are not actively transcribed and therefore not clini-
cally relevant. On the other hand, the inability of the DIPS-PCR assay to detect these 
integrated sequences may come from an alternative integration mechanism that is not 
detected by our PCR, which is based on E1 and E2 HPV sequences. Using DIPS-PCR 
with additional primers covering the entire HPV genome, Li et al.57 described a mecha-
nism for HPV16 integration in exfoliated cervical cells based on disruption of the L1 or 
L2 gene. These authors indicated that integration at these viral sites would normally not 
result in progression to (pre)malignant lesions. It is therefore likely that such integration 
events have occurred in our cell lines, before or after the clinically relevant integration 
event took place. 
From studies in cervical cancer it is known that viral load does not necessarily 
correlate to expression levels of E6 and E758. Similarly, in the HNSCC cell lines, as well 
as in primary HNSCC (see chapter 4), the variation in viral load was not reflected in the 
expression of the viral genes E2, E6 and E7. Furthermore, the current concept of cervical 
carcinogenesis suggests that HPV integration leads to disruption of the viral genome in 
the E1 or E2 open reading frame (ORF), followed by loss of the E2 inhibitory gene function 
on E6 and E7 expression59,60. Subsequently expression of both oncogenes is thought to be 
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enhanced61-63. However, in the different HNSCC cell lines, such a correlation could not be 
found. E2 mRNA levels were highly variable in UD-SCC-2, UM-SCC-47, UPCI:SCC090, 
UPCI:SCC152 and 93VU147T, even though integration was identified. A recent publica-
tion suggests that HPV integration without concurrent loss of the E2 gene can also occur 
in HNSCC resulting in viral concatenates in the human genome53. The high viral load in 
combination with a limited number of strong FISH signals indicates that integration of 
such stretches of multiple HPV-copies could have occurred in our cell lines as well. E6 
and E7 mRNA levels were equally variable in all cell lines, and no correlation was seen 
with the expression levels of E2. This is in agreement with the results obtained in primary 
HNSCC (chapter 4), in which the expression levels of E2, E6 and E7 mRNA transcripts 
were highly variable and did not show correlation to the physical status of the virus. 
In conclusion, we have characterized seven established HPV16-positive HNSCC 
cell lines, which shows viral integration in six cases and variable viral load and expression 
of early viral genes E2, E6 and E7. Furthermore they exhibit characteristics associated 
with a poor prognosis, such as EGFR overexpression and aneusomy13,48. Since these cell 
lines reflect tumors with a poor prognosis, results obtained in studies testing new treat-
ment options using these cell lines might be especially beneficial for the group of HPV-
positive HNSCC patients that respond poorly to currently used treatment modalities. 
Figure 5. Schematic representation of the possible multiplication and translocation events in the cell lines. 
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Abstract
Background and purpose: HPV associated head and neck squamous cell carcinoma 
(HNSCC) represent a distinct subgroup of HNSCC characterized by a favorable progno-
sis and a distinct molecular biology. Previous data from the randomized DAHANCA 5 
trial indicated that HPV positive tumors did not benefit from hypoxic modifications by 
Nimorazole during radiotherapy, whereas a significant benefit was observed in the HPV 
negative tumors. However, more studies have demonstrated equal frequencies of hypoxic 
tumors amongst HPV-positive and HPV-negative tumors. The aim of the present study 
was to determine radiosensitivity, the impact of hypoxia and the effect of Nimorazole in 
HPV positive and HPV negative cell lines. 
Materials and Method: The used cell lines were: UD-SCC-2, UM-SCC-047 and 
UPCI:SCC090 (HPV positive) and FaDuDD, UT-SCC-33 and UT-SCC-5 (HPV negative). 
Cells were cultured under normoxic or hypoxic conditions, and gene expression levels of 
previous established hypoxia induced genes were assessed by qPCR. Cells were irradiated 
with various doses under normoxia, hypoxia or hypoxia + 1 mM Nimorazole, and the 
clonogenic survival was determined. 
Results: The HPV positive and HPV negative cell lines exhibited similar patterns of up-
regulation of hypoxia induced genes in response to hypoxia. The HPV positive cell lines 
were up to 2.4 times more radiation sensitive than HPV negative cell lines. However, all 
HPV positive cells displayed the same response to hypoxia in radiosensitivity, with an 
oxygen enhancement ratio (OER) in the range 2.3-2.9, and a sensitizer effect of Nimora-
zole of 1.13-1.29, similar to HPV negative cells. 
Conclusions: Although HPV positive cells had a markedly higher radiosensitivity com-
pared to HPV negative cells, they displayed the same relative radioresistance under hy-
poxia and the same relative sensitizer effect of Nimorazole. The clinical observation that 
HPV positive patients do not seem to benefit from Nimorazole treatment is not due to in-
herent differences in hypoxia sensitivity or response to Nimorazole, but can be accounted 
for by the overall higher radiosensitivity of HPV positive cells.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) can be linked to the human papil-
lomavirus (HPV)1,2 and it has become evident that HPV associated HNSCC represent 
a distinct subgroup of HNSCC characterized by a distinct molecular biology , epidemi-
ology, and better prognosis3-6, leading to HPV being the most important independent 
prognostic factor in HNSCC7.
The use of HPV-associated p16 expression as a retrospective stratification param-
eter in the randomized DAHANCA 5 trial indicated a differentiated response to hypoxic 
modification dependent on the HPV status of the tumors8. Hence, HPV positive tumors 
did not benefit from hypoxic modification with Nimorazole during radiotherapy, where-
as a significant benefit was observed in the HPV negative tumors. A possible explana-
tion for this could be that HPV-positive tumors might be characterized by less hypoxia, 
which could explain both the overall improved prognosis and the lack of association with 
hypoxic modification. However, a study using a 15-gene hypoxia gene expression profile 
demonstrated the same frequencies of hypoxia amongst HPV-positive and HPV-negative 
tumors in HNSCC patients 9. Furthermore, a study evaluating the hypoxic status in HN-
SCC patients using FAZA PET scans confirmed that the HPV-positive and the HPV-
negative tumors were equally hypoxic10.
Previous in vitro studies addressing the radiosensitivity of HPV positive cell lines 
reached contradicting conclusions, with more studies pointing towards HPV positive cell 
lines being more radiosensitive than HPV negative cell lines11-13, and one study, indicating 
that HPV positive cell lines are more resistant to radiation14.
There is a  range of unresolved questions regarding the different biology and 
clinical outcome of HPV positive HNSCC, and the purpose of the present study was to 
explore the biological background for the clinical observations. Using a panel of HPV 
positive and HPV negative HNSCC cell lines we examined the hypoxia induced gene 
expression, to reveal whether the different biology of HPV positive tumors and their 
lacking response to hypoxia in radiosensitivity could be mediated through the expression 
of hypoxia induced genes. Furthermore, the radiosensitivity, the Oxygen Enhancement 
Ratio (OER), and the Sensitivity Enhancement Ratio (SER) in response to Nimorazole of 
the different cell lines was determined. 
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Method
Cell lines
The HPV-16 negative head and neck squamous cell carcinoma (HNSCC) cell lines used 
were: FaDuDD (a subline of FaDu, an undifferentiated hypopharyngeal carcinoma), UT-
SCC-5 and UT-SCC-33 (both oral carcinomas, established by Dr. Reidar Grenman, Uni-
versity of Turku, Finland15), obtained from Dr. Michael Baumann, University of Tech-
nology, Dresden, Germany). Three HPV-16 positive HNSCC cell lines: UM-SCC-047 
(from the lateral tongue, established by Dr. Thomas Carey, University of Michigan16,17), 
UD-SCC-2 (established by Dr. Thomas Hoffmann, University of Düsseldorff18,19) and 
UPCI:SCC090 (from the base of the tongue, established by Dr Susanne M Gollin, Uni-
versity of Pittsburgh20) were also used. Cells were cultured in DMEM with 10% fetal calf 
serum, 100,000 U/L penicillin, and 100 mg/L streptomycin, with 5% CO2 in a well hu-
midified incubator. 
HPV and p16 status
The presence of HPV DNA was detected by PCR in all included cell lines using the con-
sensus primer set GP5+/6+21, followed by type-specific primers for HPV16. Five μl of 
PCR product was separated on a 1.5 % agarose gel and visualized using ethidium bromide 
staining. For immunohistochemistry, cells were trypsinized, pelleted, fixed in formalin 
and paraffin embedded. Immunohistochemistry for p16INK4A was performed as previous 
described5. Briefly, paraffin sections were cut at 5 μm, heated at 60° C for 1 hour, and 
deparaffinized with EZ prep solution (Ventana Medical Systems). Heat-induced antigen 
retrieval was carried out using Cell Conditioning 1 solution (CC1, Ventana Medical Sys-
tems). p16INK4 expression was detected by using the clone JC8 (sc-56330; Santa Cruz Bio-
technology Inc, Santa Cruz, CA). Sections of p16-positive cervical carcinoma cells (SiHa) 
were used as positive controls. 
Gene expression quantification
For hypoxia experiments, 2×105 cells were seeded into 60 mm glass Petri dishes three days 
prior to experiments. Hypoxia was achieved by continually gassing the cells in an airtight 
chamber with 0% oxygen or atmospheric air, supplemented with 5% CO2 and nitrogen, 
at 37° C for 24 hours. This timepoint was based on previous data for gene expression under 
hypoxia22,23. Gene expression levels were quantified using qPCR as described in24. To detect 
transcripts of interest, 31 previously described hypoxia induced genes24,25, TaqMan Gene 
Expression assay (ABI) were used (all assay information can be found in25). Reactions were 
performed on an ABI Prism 7900 Sequence Detector (ABI). All reactions were performed 
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in duplicate. Data were analyzed using Real-Time Statminer (Intergromics) and ΔCt values 
were generated by normalizing to the geometric mean of the 3 reference genes RPL37A, 
ACTR3 and NDFIP125. For the heatmap of gene expression levels Gene Cluster 2.11 (Mi-
chael Eisen, rana.lbl.gov/EisenSoftware.htm) (median centered levels) and Java Treeview 
(ver 1.1.3) was used. Results represent data from three independent experiments.
Clonogenic assay and analysis of cell survival
To analyze the effect of oxygen concentration on radiosensitivity, clonogenic assay was 
performed. By preplating, appropriate numbers (to achieve approximately 90 colonies per 
dish) of cells (in exponential growth) were seeded into 6cm glass Petri dishes 20-24 h prior 
to irradiation. Cells were gassed for 1 h prior to irradiation in airtight chambers with ei-
ther 0% oxygen or 21% oxygen, supplemented with 5% CO2. Chambers were sealed during 
irradiation. For Nimorazole studies, 1 mM Nimorazole (based on previous published in 
vitro data26-28) was added to the cell culture media immediately prior to the hypoxia treat-
ment. Cells were irradiated with a single fraction of 1-10 Gy at a dose rate of 0.58 Gy/min 
using a 240 kV Philips X-ray machine. After irradiation, media was immediately changed, 
and the cells placed in a 5% CO2 incubator at 37° C. At 14-21 days after irradiation the 
cells were fixed in methanol and stained with 50% toluidine blue (Merck). Colonies con-
sisting of at least 50 cells were counted. The colonies were counted using Clono-Counter 
software29 and the surviving fraction was calculated. Each data point is the mean of 6-12 
samples from three independent experiments with the standard deviation shown. Survival 
curves were fitted to a linear-quadratic function using R (version 2.12.2). As control, the 
survival of cells treated with Nimorazole without irradiation was also determined.
Results
HPV and p16 status of the cell lines
The HPV-positive HNSCC cell lines have previously been characterized and demonstrat-
ed to be HPV16 positive16,17,19,30,31. Still, the HPV status of all included cell lines was vali-
dated using PCR. HPV was first detected using the general PCR-primer GP5+6+, which 
is able to detect HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 and 
LR-HPV types 6, 11, 40, 42, 43, and 4421. This confirmed that UD-SCC-2, UM-SCC-047 
and UPCI:SCC090 are HPV positive and the other included cell lines are HPV nega-
tive. Cell lines UD-SCC-2, UM-SCC-047 and UPCI:SCC090 were further tested using 
HPV16 specific primers. This showed HPV16 infection for the cell lines. The control cell 
line CaSki showed infection with HPV16 and control cell lines HeLa (HPV18 positive) 
remained negative, indicating good type-specificity (results not shown). 
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The expression level of the HPV related marker p16 was evaluated by immunohis-
tochemical staining in all the included cell lines32. The HPV positive cell lines displayed 
a clear overexpression of p16 (results not shown).
Gene expression of hypoxia inducible genes 
To test whether HPV-positive cells exhibit a different gene expression pattern in response 
to hypoxia, gene expression levels following exposure of hypoxia of 31 previous described 
hypoxia responsive genes was examined in two HPV positive and two HPV negative 
cell lines24,25. It was found that there was a great difference between the fold difference in 
expression level between the individual genes, with Ca9 displaying a difference of up to 
thousand fold, and AK3L1 being upregulated between 1.2-4.4 times. For the individual 
genes a difference in expression levels between different cell lines was also found, which 
is in line with previous studies of hypoxia induced gene expression levels in different 
cell lines 22. However, the 31 genes were all upregulated by hypoxia in all four cell lines 
(figure1). 
Radiosensitivity and impact of hypoxia in HPV positive cell lines 
To reveal mechanisms in the clinically demonstrated difference in prognosis between 
patients with HPV positive and HPV negative tumors, the radio-sensitivity of the differ-
ent cell lines in our panel was established using a clonogenic assay. It was observed that 
the HPV positive cell lines were distinctly more radiation sensitive compared to HPV 
negative cell lines, with an enhancement ratio at up to 2.4 (HPV positive cell lines: SF10% 
at 2.2-2.4 Gy, HPV negative cell lines: SF10% at 3.8-5.3 Gy) (figure 2A).
Furthermore, the impact of hypoxia on the radiosensitivity and the effect of Ni-
morazole were investigated. This revealed that the HPV positive and negative cells display 
the same response to hypoxia in radiosensitivity, with observed OERs ranging between 
2.3 and 2.9. A clear increase in radiosensitivity by Nimorazole treatment during hypoxia 
exposure was seen with the HPV positive (SER 1.1-1.2) and HPV negative (SER 1.1-1.3) 
cell lines (figure 2B-2G). 
Control experiments with cells treated with Nimorazole without irradiation demon-
strated that Nimorazole by itself had no influence on clonogenic survival (results not shown).
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Figure 1.
A)  Gene expression under hypoxia. Relative gene expression of 31 genes under hypoxia, normalized to the gene expres-
sion level under normoxia. Data are the mean values of three independent experiments. Error bars represents standard 
deviation (n=3). 
B)  Heat map of the 31 genes. Data from three independent experiments are shown. The colour bar is showing the fold 
change relative to the median expression of each gene across all cell lines and conditions. Data is log2 transformed.
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Figure 2. Radiosensitivity of cell lines. 
A)  Cell survival curves of all included cell lines under normoxia. 
B-F)  The individual cell lines cells after irradiation under either normoxic, hypoxic or hypoxia+ 1mM Nimorazole con-
ditions. The linear quadratic model is fitted to the data. The OER and SER is calculated at SF10%. The error bars 
represents the standard deviations (n=6-12).
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Discussion
There is a range of unresolved questions regarding the different biology and clinical out-
come of HPV positive HNSCC, and the purpose of the present in vitro study was to 
explore the biological backgrounds for the clinical observations. In this study we have 
used a panel of HNSCC cell lines, including three HPV positive HNSCC cell lines, all 
three HPV16 positive. The UPCI:SCC90 and UM-SCC-047 cell lines have previously 
been shown to contain integrated HPV16 DNA while this is not confirmed for UD-
SCC-212,30,33. All three cell lines express the viral E6 and E7 genes31.
It is possible that the difference in patient outcome and sensitivity to hypoxia is 
mediated through hypoxia responsive genes, the key regulators of metabolic and cellular 
adaptation to hypoxia. Repression of the hypoxia induced pathways may severely com-
promise cell survival under hypoxia, leaving only the more oxygenated cells viable. The 
present study investigated the gene expression levels of a range of previous described hy-
poxia responsive genes, following exposure of hypoxia. It was found that for all cell lines, 
the investigated genes were upregulated during hypoxia. Many of the included genes, Ca9 
for example, are HIF1 regulated, indicating that the function of HIF1 is not compromised 
in HPV positive cells. Fifteen of the tested genes are included in a hypoxia gene expres-
sion profile9,25,34, that has previously demonstrated to have predictive impact for hypoxic 
modification of radiotherapy in head and neck cancer. The results in the current study 
also confirm the use of this hypoxia gene expression classifier, regardless of HPV status. 
The investigation of the effect of hypoxia and Nimorazole on the radiosensitivity 
of the different cell lines revealed that all cell lines exhibited a comparable OER and SER. 
This suggests that the clinical observation that HPV positive patients do not benefit from 
Nimorazole treatment is not due to a  difference in hypoxia sensitivity or response to 
Nimorazole. We observed as SER with Nimorazole in the range of 1.13-1.29, which is in 
line with previous published data27,35 . The concentration of Nimorazole used in this study 
(1 mM) is comparable to the level in the tumor in patients treated with Nimorazole36-38.
Overall, the HPV positive cell lines exhibited a markedly higher radiosensitivity, 
which has also been reported for the same HPV positive cell lines in a very recent paper13, 
leading to HPV positive cells under hypoxia exhibiting approximately the same radio-
sensitivity as HPV negative cells under normoxia. This opens for the possibility, that with 
the current clinical radiation schedule, HPV positive tumors receive a radiation dose at 
a  level that makes the use of Nimorazole unnecessary. It is therefore possible that the 
observed increased radiosensitivity may account for both the favorable clinical prognosis 
as well as the observed lack of effect of Nimorazole treatment in HPV positive patients. 
Due to the good treatment response, a dose reduction for patients with HPV-positive 
oropharyngeal cancers has been suggested. The finding that Nimerazole in principally 
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active in HPV-positive HNSCC cells in vitro suggests that Nimerazole could be indicated 
and beneficial in HPV-positive HNSCC when treated with a lower total dose of radiation, 
than what is current practice. 
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Head and neck carcinomas are the sixth most common cancer by incidence worldwide 
and their mortality rate ranges from 40-50%1. Most of them arise from the mucosa of 
the upper aerodigestive tract (oral and nasal cavity, paranasal sinuses, pharynx, larynx, 
and the trachea) and about 90% of these malignancies are head and neck squamous cell 
carcinomas (HNSCC). For many decades the most important risk factors for the develop-
ment of HNSCC were tobacco- and alcohol (ab)use and poor oral hygiene. However, in 
the last decades an increasing role of high-risk (HR) human papillomaviruses (HPV) in 
the carcinogenesis of HNSCC has become evident.
Remarkably, at the same time, the incidence of HNSCC in specific anatomical 
sites has declined with an annual change of 1.4% from 1992-20052, which correlates 
to a decrease in the prevalence of smoking. In the US, the prevalence of smoking has 
declined from 42.4% in 1965 to 18.9% in 20113. Not only do fewer people smoke, the 
number of smoked cigarettes per day has decreased as well3. However, the incidence of 
oropharyngeal carcinomas has increased. This was demonstrated by a study from the 
US, where a significant increase was shown for cancers arising from the base of tongue 
and tonsil from 1973-20044 and Swedish study showing an increased incidence of ton-
sillar cancers in the period between 1970 and 20065 from 0.74/100.000 person/years 
to 1.65/100.000 person/years. This rise was accompanied by an increased prevalence 
of HPV in oropharyngeal cancers, and particularly in tonsillar carcinomas5,6.This sug-
gests a prominent role for HPV infection in head and neck carcinogenesis. Since HPV 
is the most commonly sexually transmitted infection, the increasing frequency of HPV 
infections in general, and pharyngeal HPV infections in particular, might result from 
a change in sexual behavior. 
Dillner and coworkers7 showed that seropositivity for HPV and for Chlamydia 
trachomatis could be used as markers for sexual behavior, in particular for the number of 
sexual partners. Since then, several studies have associated high-risk sexual behavior with 
HR-HPV infection8. Furthermore, these studies have unequivocally shown that infection 
with HR-HPV is a significant independent risk factor for the development of HNSCC9-11. 
HPV-related HNSCC differ from non-HPV-related HNSCC with respect to mo-
lecular and clinicopathological parameters. Patients with HPV-positive HNSCC tend to 
present with smaller primary tumors at first diagnosis, have a lower tobacco- and alcohol 
intake, and are diagnosed at a slightly younger age. HR-HPV-positive tumors further-
more show a more baseloid appearance, downregulation of p53 and pRb and overexpres-
sion of p16INK4A, p14ARF, p18INK4C and p21Cip1/WAF1 (chapter 1). 
Patients with HPV-negative HNSCC almost always have a history of tobacco- and/
or alcohol (ab)use12. However, there is a large sub-group of patients with HPV-positive 
carcinomas that also present with these risk factors12. Tobacco smoking has even been 
associated with an increased risk of HPV infection in men that do not show high-risk 
sexual behavior13. Although patients with HPV-related HNSCC generally have a  lower 
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risk to develop a second primary tumor (SPT) compared to patients with HPV-negative 
tumors, smoking was also shown to significantly increase the risk to develop SPTs in 
patients that were seropositive for HPV14. 
Therefore, it is important to make a distinction between HPV-positive tumors 
and tumors that arise from a  clinically relevant HPV infection. A helpful model for 
stratification has been proposed by Weinberger et. al.15. In this study, three biologically 
and clinically distinct classes of oropharyngeal squamous cell carcinomas are recog-
nized. Class I tumors are associated with tobacco and alcohol consumption and do not 
contain HPV. Class II tumors are alcohol/tobacco-related, and also contain HPV DNA, 
but do not show overexpression of p16INK4A, the surrogate marker for HPV-infection. 
These tumors, although HPV DNA-positive, show clinicopathological characteristics 
that resemble alcohol/tobacco-related tumors, which indicates that infection of the tu-
mor site with HR-HPV has after the onset of oncogenesis. Class III contains etiologi-
cally HPV-related tumors, as shown by the overexpression of p16INK4A. The reliability of 
a test algorithm for the detection of active HPV in FFPE tumor samples, consisting of 
p16INK4A and subsequent detection of HR-HPV by GP5+/6+ on the positive cases, was 
recently validated16.
The differentiation between HPV-induced and tobacco/alcohol-associated HN-
SCC offers new opportunities for treatment stratification. For the patient population pre-
senting with class III tumors this could implicate treatment deintensification, thereby 
reducing treatment-related morbidity without affecting outcome. It has already been 
shown in numerous studies that patients with HPV-positive carcinomas show a better 
prognosis as compared to HPV-negative cases. A recent review and meta-analysis17 estab-
lished that patients with HPV-related HNSCC had a 54% reduced risk of overall mortal-
ity. This is in line with the studies described in chapters 1 and 2, which show that HPV-
associated HNSCC are more often diagnosed at a lower T-stage, making them more often 
eligible for radical local therapy, in most cases consisting of surgery followed by adjuvant 
radiotherapy. These patients had a far more favourable prognosis as compared to patients 
treated with primary radiotherapy. One could therefore argue that the better prognosis 
of HPV-positive patients might be caused by earlier detection of the primary tumor, due 
to early detection of metastases (chapters 1 and 2), thereby influencing disease outcome. 
These patients also tend to be younger, which might result in lower mortality rates18. 
Studies in primary HNSCC as well as in cell line models, have shown that HPV-
positive cells are more sensitive to radiation therapy than their HPV-negative counter-
parts19,20. Although hypoxia is an important factor that negatively influences prognosis 
of patients21, hypoxic modification by Nimorazole did not increase radiosensitivity in 
HPV-positive tumors, whereas it did improve therapeutic response in HPV-negative tu-
mors19. This might indicate that HPV-positive cells intrinsically have a better response to 
radiotherapy, which might be caused by a compromised DNA repair capacity20. All in all, 
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studies describing the efficacy of the different treatment modalities in HNSCC conclude 
that HPV-positive tumors have a better survival rate than HPV-negative tumors, irre-
spective of therapeutic approach22-27. 
Since it is evident that patients with HPV-positive tumors have a better prognosis, 
an important question is whether this patient population would benefit from modified 
treatment protocols. However, many of the future treatment options for patients with 
HPV-positive tumors, as discussed in chapter 1, are still in a developmental phase and as 
such, cannot yet be implemented in the current treatment protocols. In addition, patients 
with HPV-associated HNSCC do not represent a homogenous cohort. Instead, this group 
comprises patients that may exhibit characteristics associated with a poor prognosis, such 
as a history of smoking or overexpression of EGFR in the tumor. Therefore, it is likely that 
smoking, alcohol, tumor hypoxia and HPV-infection all represent independent risk- and 
prognostic factors for the development and progression of HNSCC. So, rather than strati-
fying patients according to HPV-status of the tumor, a better option would be to develop 
personalized treatment protocols. A useful model for such an individualized approach 
has been introduced by Ang and coworkers22, which have divided patients with HNSCC 
into three risk groups, depending on HPV-status, nodal involvement and tobacco smok-
ing. Whether patients classified as being low-risk according to these criteria could benefit 
from deintensified treatment protocols without affecting long-term survival, is a highly 
relevant question which still remains to be answered. 
In addition to the conventional treatment protocols, development of antiviral 
therapies could be beneficial for all patients with HPV-induced carcinomas. The efficacy 
of these agents, however, may depend on the physical status of the virus, i.e. episomal or 
integrated. It was shown that interferon therapy can result in a selective growth advan-
tage of cells with integrated HPV28,29. Strategies aiming at inhibition of viral replication, 
for example using artificial zinc fingers30,31, are only effective in episomal HPV infection. 
It will thus be imperative to include the viral integration status in future stud-
ies concerning antiviral therapy. For HNSCC there is much controversy in reported 
integration frequencies and furthermore the question remains whether or not there 
are preferred sites for viral integration in these head and neck malignancies. There-
fore, the HPV-integration status was retrospectively analyzed in a cohort of 75 patients 
(chapters 3 and 4) as well as in seven cell lines that were derived from HPV-associated 
HNSCC (chapter 5). 
Viral integration appeared to occur randomly throughout the human genome, 
although integration was also detected in previously reported integration clusters32, in 
both primary tumors and cell lines. Viral E2, E6 and/or E7 gene expression was detected 
in all cell lines, and in all but three tumor samples, irrespective of the physical status 
of the virus. Gene expression varied widely, indicating that a constitutive, rather than 
a high expression of viral oncogenes is required for HPV-induced HNSCC. While vi-
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ral integration may perhaps not have a significant influence on the current treatment 
protocols, the integration status might still be a relevant factor in the treatment of these 
tumors with antiviral drugs. 
A comparison between the results obtained in primary HPV-positive HNSCC 
and established HPV-positive HNSCC cell lines revealed that the detected integration 
frequency in primary tumor samples was considerably lower (40%) than in the cell lines, 
where we detected integration in six out of seven cell lines. 
On the one hand, the high percentage of integration in cell lines might suggest 
a preferential clonal expansion of tumor cells containing integrated viral DNA. On the 
other hand, it might also be explained by the inability of the used PCR technologies to de-
tect all integration events, in particular in the primary tumors. A recent paper by Li et al.33 
describes additional integration mechanisms which are not covered by the conventional 
procedures that were used in chapters 3, 4 and 5. 
Furthermore, the FISH analysis usually shows only one or two signals per nucleus in 
the primary tumor samples where integration was detected (chapter 4), while most cell lines 
showed two or more integration signals per nucleus. This is most probably related to the 
chromosomal stability of the primary tumor cells, which has been described to be associated 
with HPV-positivity34. However, most cell lines showed copy number imbalances, indicat-
ing genomic instability, explaining the presence of multiple signals for integrated HPV. 
For the development of new therapeutic options, as well as for a deeper under-
standing of the etiology and biological mechanisms involved in the development of 
HNSCC, cell line models are indispensable. However, it is important to keep in mind 
that cell lines are not a perfect representation of the initial tumor. Cell lines grow in 
a well-controlled and optimized environment, while tumors growth is influenced by 
a variety of factors. Furthermore, clonal expansion and therefore selection of tumor 
cells occurs with the establishment of a  cell line, whereas primary tumors represent 
a heterogeneous cell population. 
Moreover, it was shown that tumor and patient characteristics influence the suc-
cess rate of HNSCC cell line establishment. A statistically significant positive association 
was found between the establishment of cell lines and 11q13 amplification, nodal status 
and alcohol consumption, while a negative association was found for HPV-positivity35. 
This suggests that cell lines can be more readily established from tumors with character-
istics that are associated with a poor prognosis. The HPV-positive HNSCC cell lines used 
in chapter 5 were mostly established from metastatic tumors in patients with a history of 
smoking. Furthermore these cell lines all show elevated levels of EGFR expression when 
compared to primary tumors. These factors are again all indicators of a poor prognosis. 
Therefore the results obtained in studies testing new treatment options using these cell 
lines might be especially beneficial for the group of HPV-positive patients that respond 
poorly to current treatment modalities. 
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An important factor in determining the response to treatment is the presence 
of hypoxic regions the tumor. In particular in head and neck carcinomas, hypoxia as-
sociated with a poor outcome21,36, and HPV-positive and -negative tumors were found 
to be equally hypoxic37. Since the effect of radiotherapy depends on the degree of tis-
sue oxygenation, hypoxia is most extensively studied in relation to radiotherapy. Free 
radicals, produced by tissue irradiation, are stabilized by the presence of oxygen, leading 
to increased DNA damage. Therefore, compounds that mimic oxygen, such as nitro-
imidazols, can sensitize hypoxic cells to the effects of radiation therapy. In Denmark, 
one such compound, Nimorazole, is already being used in the standard treatment of 
patients with head and neck tumors. The combination of Nimorazole administration 
and radiotherapy for patients with HNSCC significantly reduced disease-specific death 
after 5 years38. As expected, HPV-positive HNSCC patients showed significantly im-
proved outcome after radiotherapy, but no effect of Nimorazole addition was seen39. This 
could indicate that hypoxia is less frequently present in HPV-positive tumors. To assess 
whether the lack of response to hypoxia modification in HPV-positive primary HNSCC 
could be explained by a difference in the expression levels of hypoxia-induced genes, 
a panel of HNSCC cell lines was studied (chapter 6), showing that HPV-positive and 
-negative cell lines exhibit similar expression levels of hypoxia-inducible genes. Despite 
this similarity, HPV-positive cell lines exhibited markedly higher radiosensitivity that 
HPV-negative cell lines, and show a better response to radiotherapy after addition of 
Nimorazole. These results indicate that Nimorazole could be beneficial in HPV-positive 
HNSCC when treated with a lower total dose of radiation therapy. 
Mapping differences between HPV-positive and -negative tumors may provide 
additional possibilities for new therapeutic targets. In particular, a recent study showed 
a significant association of PIK3CA mutations or copy number alteration, as well as PTEN 
inactivation with HPV-status of the tumor. These genes are involved in the PI3K/AKT/
mTOR pathway, and studies assessing the effectiveness of mTOR inhibitors have shown 
that xenografts of HPV-positive HNSCC cell lines in mice were highly sensitive to ra-
pamycin and RAD00140. A recent study also showed a significant association of FANCC 
and PTCH1 alterations with prognosis41, which might provide targets for molecular ther-
apy irrespective of the tumor HPV-status. 
All in all, it is evident that HPV-positive HNSCC show clinicopathological and 
molecular characteristics that are different from HPV-negative tumors. However, prog-
nostic indicators such as tobacco and alcohol consumption, EGFR-overexpression, hy-
poxia as well as HPV-positivity of the tumor, cannot be seen as isolated factors. Although 
novel therapeutic options should definitely be explored to optimize patient treatment, 
another approach that should be examined is a more personalized protocol for individual 
patients by stratifying patients based on multiple prognostic factors. 
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Summary
The aim of this thesis was to enhance our understanding of clinical and biological features 
of HPV-associated oropharyngeal carcinomas.
The first chapter gives an introduction to the molecular and clinicopathological differ-
ences between HPV-positive and HPV-negative tumors. HPV-associated HNSCC are 
considered to form an etiologically distinct group of carcinomas with typical clinical and 
molecular features. HPV-positive tumors are characterized by overexpression of the on-
coproteins E6 and E7, p16INK4A, p18INK4C and p21Cip1/WAF1 as well as downregulation of p53 
and pRb. Patients tend to be slightly younger and present with more advanced disease 
and smaller primary tumors at diagnosis. Current treatment modalities and the effect of 
HPV-status on disease outcome are discussed. In addition, benefits of prospective thera-
peutic options are reviewed. 
Chapter 2 involves a clinical study in which the prognostic value of N-status in a cohort 
of 81 patients with tonsillar cancer was examined. HPV-positive patients presented with 
significantly smaller tumors at diagnosis, whereas the frequency of nodal involvement 
was equal to HPV-negative patients. The presence of nodal involvement seemed to be 
related to an unfavourable prognosis in HPV-negative patients, but seemed to be related 
to a better survival in HPV-positive patients. 
Chapter 3 describes the analysis of tumor biopsies from a  cohort of 75 patients with 
HPV-associated HNSCC to assess integration frequency and identify integration loci. An 
integration frequency of 39% was detected in these tumors using APOT- and DIPS-PCR. 
Integration loci were distributed throughout the genome, targeting most chromosomes 
except chromosomes 11, 16, 19, 20, 21 and X. Integration events occurred in transcribed 
regions in 73% of cases. 
In chapter 4 the viral physical status was correlated to the expression of the viral E2, E6 
and E7 genes and to a number of virally-disrupted human genes. This showed that the ex-
pression of a gene invaded by HPV does not show significant differences when compared 
to the expression of that gene in samples where HPV has not disrupted it. Analysis of the 
viral gene expression showed large variation in the levels of E2, E6 and E7 expression, in-
dependent of the HPV integration status. Assessment of the viral load did not reveal any 
significant associations to the integration status or the expression of viral genes. 
Chapter 5 involves the characterization of 7 HPV-associated HNSCC cell lines to further 
study integration and to establish a reliable cell line model for HPV-associated HNSCC 
cancers. Viral integration was shown in six of the seven cell lines using APOT- and DIPS-
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PCR as well as FISH. Identified integration loci were verified using double-target FISH 
analysis. Viral load and viral gene expression varied considerably amongst the cell lines 
and all cell lines expressed EGFR. 
The effects of radiation and hypoxia were assessed in chapter 6 using a panel of HPV-
positive HNSCC cell lines. These three cell lines displayed a markedly higher radiosensi-
tivity but were equally affected by hypoxia-modification by Nimorazole treatment when 
compared to HPV-negative HNSCC cell lines. 
Finally, in the general discussion and future prospects the results of the findings as de-
scribed in chapters 1 to 6 are discussed in a broader context. Moreover, suggestions for 
future research are presented. 
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Samenvatting 
Het doel van het huidige proefschrift was om het begrip van klinische en biologische 
eigenschappen van HPV-gerelateerde hoofd-halskankers te vergroten. 
Het eerste hoofdstuk geeft een inleiding in de moleculaire en klinisch-pathologische ver-
schillen tussen HPV-positieve en –negatieve tumoren. HPV-geassocieerde hoofd-hals 
plaveiselcelcarcinomen worden beschouwd als een etiologisch verschillende groep car-
cinomen met specifieke klinische en moleculaire eigenschappen. HPV-positieve tumo-
ren worden gekenmerkt door overexpressie van de oncoproteinen E6 and E7, p16INK4A, 
p18INK4C en p21Cip1/WAF1 evenals downregulatie van p53 en pRb. De patiënten zijn jonger 
en worden gediagnosticeerd in een verdergevorderd stadium met een kleinere primaire 
tumor. De huidige behandelingsmogelijkheden en het effect van HPV op de uitkomst van 
de ziekte worden besproken. Daarnaast wordt een overzicht gegeven van prospectieve 
behandelingsopties. 
In hoofdstuk 2 wordt een klinische studie behandeld, waarin de prognostische waarde 
van de N-status wordt onderzocht in een cohort van 81 patiënten met tonsilcarcinomen. 
HPV-positieve patiënten hadden een significant kleinere tumor op het moment van di-
agnose, terwijl de lymfeklieren in gelijke mate aangedaan waren. De aanwezigheid van 
positieve lymfeklieren leek gerelateerd te zijn aan een ongunstige prognose in HPV-ne-
gatieve patiënten, terwijl dit gerelateerd was aan een betere overleving in HPV-positieve 
patiënten. 
In hoofdstuk 3 wordt de analyse beschreven die uitgevoerd is op tumor biopsieën ver-
kregen van een cohort van 75 patiënten met HPV-gerelateerde hoofd-halskanker, om de 
integratiefrequentie en integratielocus te bepalen. Een integratiefrequentie van 39% is in 
deze tumoren vastgesteld door middel van APOT- en DIPS-PCR. Integratieloci waren 
verspreid over het gehele genoom en alle chromosomen, met uitzondering van chromo-
soom 11, 16, 19, 20, 21 en X, waren aangedaan. Integratie werd in 73% van de gevallen 
gevonden in getranscribeerde chromosomale regio’s. 
In hoofdstuk 4 is gekeken naar de fysieke status van het virus in relatie tot de expressie 
van de virale genen E2, E6 en E7 en een aantal humane genen die door virale integratie 
verstoord zijn. Dit onderzoek heeft aangetoond dat de expressie van een gen dat door 
HPV is verstoord, niet verschilt van de expressie van dat specifieke gen in tumoren waar 
HPV dit gen niet heeft aangedaan. Analyse van de virale genexpressie liet een grote varia-
biliteit in de hoogte van E2, E6 en E7 expressie zien, onafhankelijk van de integratiestatus 
van HPV. Bepaling van het aantal virusdeeltjes per cel liet geen significante relatie zien 
met de integratiestatus van het virus, noch met de expressie van de virale genen. 
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Hoofdstuk 5 beschrijft de karakterisatie van 7 HPV-gerelateerde hoofd-hals plaveisel-
celcarcinoma cellijnen, waarin de virale integratie verder geanalyseerd wordt en de be-
trouwbaarheid als model voor HPV-gerelateerde hoofd-hals plaveiselcelcarcinomen 
werd vastgesteld. Virale integratie kon in zes van de zeven cellijnen worden aangetoond 
middels zowel APOT- en DIPS-PCR als FISH. De geïdentificeerde integratieloci werden 
geverifieerd met behulp van double-target FISH analyse. Het aantal virusdeeltjes per cel 
en virale genexpressie van de geanalyseerde cellijnen varieerden aanzienlijk en in alle cel-
lijnen kon EGFR expressie worden aangetoond. 
De effecten van bestraling en hypoxie werden geanalyseerd in hoofdstuk 6. Hiervoor 
werd gebruik gemaakt van een panel van HPV-positieve hoofd-hals plaveiselcelcarcino-
ma cellijnen. Deze drie cellijnen toonden een duidelijk hogere gevoeligheid voor bestra-
ling maar werden in gelijke mate beïnvloed door hypoxie-modificatie door behandeling 
met Nimerazole in vergelijking met HPV-negatieve hoofd-hals plaveiselcelcarcinoma 
cellijnen.
Ten slotte worden in de algemene discussie en toekomstverwachtingen, de bevindingen, 
beschreven in de hoofdstukken 1 tot en met 6, in een bredere context bediscussieerd. 
Bovendien worden suggesties voor toekomstig onderzoek beschreven. 
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